# INDEX TO VOLUME 178

## Author Index


Abadi, J., 707
Abate, D. A., 1145
Abbott, L. Z., 1610
Aberg, J. A., 1446
Abernathy, E. S., 642
Abrams, E. J., 101
Abrams, W. R., 1635
Abrutyn, E., E1
Acheson, D., 185, 1369
Adachi, M., 127
Adams, J. A., 138
Adams, O., 544
Adams, V., 841
Adcock, P. M., 577
Adjami, A., 282
Agnello, D., 471
Ajello, G., 266
Akamatsu, T., 717
Alessandrini, A., 488
Al-Harthi, L., 1343
Alkrinawi, S., 1081
Allard, A., 274
Allen, M., 1497
Allos, B. M., 1228
Alsina, M., 846
Al-Tawfiq, J. A., 1684
Altekruse, S., 752
Alter, M. J., 1579
Amador, J. J., 1457
Ambrosino, D. M., 1555
Amici, C., 564
Anastasiou-Katsiardani, A., 1734
Anderson, E. L., 870
Anderson, L. J., 925
Ando, T., 1571
Andrle, G. A., 138
Angeletti, S., 1743
Anguita, J., 1512
Angulo, F. J., 172
Annunziato, P., S48, 539
Antony, V. B., 1450
Aono, T., 1244
Apgar, C. L., 1193
Apter, A. J., 318
Aquaro, S., 413
Arany, I., 551
Arden, N. H., 53
Arias, G., 1177
ARIEL Project Investigators, 1317
Aries, S. P., 891
Arndt, R., 252
Arno, J. N., 1713
Arnow, P. M., 783
Aronson, N., 1799
Arrowood, M. J., 827
Artin, K. H., S104
Arvin, A. M., S22, S39, S43, S64, 940
Ashford, D. A., 1457
Ashkenazi, S., 535
Ashley, R. L., 1
Assmar, M., 1852
Ausiello, C. M., 466
Australian IL-2 Study Group, 992
Aversa, J., 1198
Aziz, N., 423
Azuma, T., 1391
Azzari, C., 862
Baarsma, G. S., 27
Bacci, A., 1750
Back, C., 282
Bacq, Y., 556
Badaro, R., 1488
Badary, S., 512
Bagarazzi, M. L., 92
Bahktiari, M., 1497
Bailleux, F., S99
Bain, C., 1263
Baine, Y., 92
Baird, J. K., 592
Baker, C. J., 539
Bales, B., 1202
Balfour, H. H., Jr., 297, 531
Balish, E., 478
Balk, A. H. M. M., 256
Ballesteros, M., 1228
Ballou, W. R., 1139
Balslev, U., 1334
Balsley, J., 1555
Bamji, M., 101
Barakett, V., 270
Barber, D., S109
Barin, F., 556
Barreto-de-Souza, V., 1847
Barth, S. S., 172
Barthold, S. W., 1512
Bartlett, J. A., 1170, 1803
Bartlett, M. S., 1767
Basri, H., 592
Bassetti, D., 488
Basso, L. A., 769
Batsford, S., 1676
Baughman, R. P., 1767
Baum, M., 547
Becherer, P. R., 1181
Beckerman, K., 368
Beckmann, E.-R., 252
Bekker, L.-G., 580
Belch, J., 294
Belisle, J. T., 1534
Belknap, S. M., 1075
Bell, B. P., 1579
Belshe, R. B., 870
Benike, C. J., S39
Berend, C., 1170
Berg, D. E., 220
Berger, R., S99
Bergeron, M. G., 1472
Bergeron, Y., 1472
Bermudez, L. E., 896
Bernigaud, A., 792
Bersoff-Matcha, S. J., 1174
Bertino, J. S., Jr., 1181
Best, J. M., 642
Bethel, J., 80
Bethell, R. C., 1257, 1592
Betts, P. W., 850
Beyrer, C., 243, 1507
Bhat, G., 1787
Bhattacharjee, A., 1205
Bhatti, S. U., 1217
Biggar, R. J., 304
Bilello, J. A., 360
Binsztein, N., 266
Birgander, L. S., 274
Birx, D. L., 1040, 1306, 1799
Bisceglia, M., 1373
Bishop, R., 752
Bitzan, M., 1551
Blackwelder, W. C., 45
Blair, C. S., 1779
Blais, V., 1369
Blanchard, H., 270
Blanchard, J. S., 769
Blanche, S., 1019
Blank, K. J., 227
Blaser, M. J., 213
Bloem, A. C., 1279
Boatin, B. A., 282
Boccia, M. C., 1373
Boeckh, M., 1153
Bofill, M., 1166
Bohm, R. P., Jr., 722
Boivin, G., 297, 1545
Bolin, C. A., 1457
Boman, J., 274
Boom, W. H., 1105
Boon, R. J., S76
Boralevi, F., 1546
Borelli, S., 603
Borkowsky, W., 1047
Borleffs, J. C. C., 1279
Bornay-Llinares, F. J., 820
Bornstein, S. R., 887
Borrell, N., 531
Bosma, T. J., 642
Boucaud, D., S34
Boucher, C. A. B., 1279
Bova, J. L., 783
Bowden, R. A., 1153
Boyer, C. B., 1202
Boyer, J. D., 92
Bozette, S. A., 922
Brady, M. T., 776
Bragg, S. L., 1457
Braun, J., 891
Bray, M., 651
Bremer, J. W., 560
Brennan, D. C., 626
Brenner, M. K., 1257
Brites, C., 1488
Brochu, P., 1492
Brodine, S. K., 1202
Brooks, J. L., 451
Brouwer, M., 1806
Brown, B. A., 121
Brown, J. M., 1539
Brown, L., 1181
Brown, M., 1530
Brown, M. R., 1095
Brown, T., 101
Brundage, J. F., 1776
Bruzzese, E., 1373
Bryan, J. P., 1181
Bryson, Y. J., 375
Bucci, J. G., 968
Bucci, K., 512
Buchbinder, S. P., 669
Buckingham, S., 1555
Bui, E., 1019
Bukh, J., 1193
Bukusi, E., 1352
Buller, R. S., 626
Burchett, B. M., S67
Burda, S., 1502
Burgard, M., 1019
Burgess, D. C. H., 1852
Burgess, M., S64
Burke, R. L., 1, 8
Burns, W. H., 618
Burstein, E., 147
Busch, M. P., 1163
Buseyne, F., 1019
Bush, M., 1719
Busseniers, A. E., 45
Buurman, W. A., 883, 1839
Buzby, J. C., 1228
Bwayo, J. J., 983, 1352
Calió, R., 413
Callister, S. M., 733
Camorlinga-Ponce, M., 1089
Campadelli-Fiume, G., 841
Campbell, T. B., 1488
Canani, R. B., 1373
Canessa, A., 488
Cantwell, M., 334
Cao, K., 1799
Cao, Y., 1317
CAP Study Group, 1075
Carlin, D., 1555
Carlson, R. W., 1075
Carr, A., 992, 1812
Carranza, C., 1434
Carreño, V., 247

Cartwright, K. A. V., 451
Carvalho, E. M., 1856
Casadevall, A., 1761
Cassell, G., 1526
Cassone, A., 466
Cauci, S., 1698
CDC Perinatal AIDS Collaborative Transmission Study Group, 680
Cedillo-Rivera, R., 1089
Celentano, D. D., 1507
Çelik, J., 1379
Celum, C. L., 978
Cenci, E., 1750
Centor, R. M., 921
Chaisson, R. E., 1642
Chambers, L. O., 603
Chan, C., S109
Chan, C. Y., S95, S104
Chan, I. S. F., 1181
Chandiwana, S. K., 289
Chandler, D. B., 1149
Chandran, B., 547
Chang, P. C. L., 207
Chanock, S. J., 589
Chapman, B. A., 1726
Chapman, S. W., 1726
Chappell, C. L., 827, 900
Charboneau, D., 431
Chart, H., 920
Chatlynne, L., 304
Chattergoon, M. A., 92
Chauvin, P., 270
Che, M., 1000
Chehrenama, M., 1228
Chen, C.-Y., 243, 1688
Chen, S.-H., 618
Chen, T.-C., 866
Chern, K. C., 1149
Chernoff, D., 1047
Cherrington, J. M., 1821
Chesney, R. W., 596
Cheung, C. Y., 1250
Childers, T. A., 968
Chintu, C., 1787
Chiozzi, M. H., 70
Chiu, S. S., 1250
Cho, E., 1783
Cho, S.-N., 138
Chodakewitz, J., 360
Chohan, B. H., 441, 983
Chou, S., 526
Chou, T., 783
Christodoulides, M., 451
Christophers, E., 252
Christopherson, C., 375
Chrousos, G. P., 887
Chu, C.-M., 866
Ciccarelli, R. B., 92
Cinti, S., 1530
Cisneros, R. L., 200
Clark, W. S., 680
Clarke, M. J., 53
Cleary, J. D., 1726
Clements-Mann, M. L., 1502
Clemons, K. V., 1217
Cockerill, F. R., III, 584
Coen, D. M., 618
Coffey, M., 1530
Cohen, C. R., 1352
Cohen, J., 1139
Cohen, J. I., 310
Coleman, K. T., 8
Coleman, P. J., 954
Collatz, E., 159
Collier, A. C., 349
Collins, J., 1530
Condra, J., 360
Coney, L. R., 92
Connick, E., 70
Contopoulos-Ioannidis, D. G., 349
Conway, B., 662
Cookson, S. T., 266
Cooper, D. A., 349, 858, 992, 1812
Cooper, P. J., 1133
Coovadia, H., 1327
Corbett, K. M., 642
Corey, L., 1, 349, 603, 978, 1616
Cornelissen, J. G. C., 27
Corrales, J. L., 266
Costlow, C., S104
Cosyns, M., S95
Cotsonis, G., 680
Couch, L., 121
Couldwell, D., 858
Coulter, C. L., 1000
Coutinho, R. A., 397, 1024, 1806
Cox, J. H., 1040, 1306
Cox, N. J., 53
Cox, R. J., 933
Crawford-Miksza, L., 1776
Creusvaux, H., S99
Cripps, A. W., 1667
Crisostomo, F.-M., 1
Cromie, R., 1719
Cron, S., 900
Crooks, R. J., S71, S81
Cross, J. V., 1105
Crouse, D. T., 1122
Cruz-López, A., 820
Cunningham, P., 858, 1812
Currier, M. M., 1060
Cutler, A., 460
Dagan, R., 1081, 1548, 1843
Dale, D., 1075
Dalhoff, K., 891
Dalod, M., 61
Daniel, R. W., 45
Dankert, J., 220, 1067, 1231
Dankner, W. M., 776
D'Arc Roe, J., 70
da Silva, A. J., 820
DATRI 002 Study Group, 80
Däubener, W., 875
Davenny, K., 560
Davidkin, I., 1567
Davidson, F., 1779
Davidson, M. G., 503
Davis, C., 1635, 1799
Davis, D. A., 413
Davis, K., 651
Dawson, D., 1803
Dayhoff, D. E., 1799
Dean, D., 1707
DeBoisblanc, B., 1075
Deckelbaum, R. J., 1081
de Fatima Melo, M., 1488
Degrave, W., 911
DeGruttola, V., 340
de Jonge, N., 256
de la Luz Sanchez, M., 334
Del Bono, V., 488
de Leeuw, N., 256
de Lencastre, A., 164
Delfraissy, J. F., 1816
de los Reyes, J. O., 1457
Del Sero, G., 1750
de Martino, M., 862
DeMasi, R., 1803
Demchuk, B., 1115
Demouchy, C., 1158
Denayrolles, M., 1546
Deng, J.-H., 846
Dennehy, P. H., 1555
Deresinski, S. C., 1177
Derouin, F., 904
Deschemin, J.-C., 61
DesJardin, J. A., 1783
deSouza, M., 1040
Detels, R., 423
Deubel, V., 1270
Deutsch, P., 360
Deveikis, A., 375
DeVincenzo, J., 1555
de Vos, N. M., 1279
de Wolf, F., 397, 1008
Dicker, D., 1623
Dickes, J., 1795
Dickover, R. E., 375
Dief, A. D. E., 512
Dietze, R., 1115
Dillon, J. J., 783
Dillon, M., 375
Di Luca, D., 841
Dinarello, C. A., 1830
Dings, M. E. M., 27
Dirnitriadou-Georgiadou, A., 1734
Dohn, M. N., 1767
Donegan, P., 1707
Donelli, G., 564
Donkersloot, J. A., 700
Donohoe, W., 815
Dorman, S. E., 1095
Dornadula, G., 1623
DosReis, G. A., 1847
Doss, M., 1
Dowler, M., 1139
Draper, D., 815
Drevets, D. A., 1658
Drew, W. L., 526, 1821
Driussi, S., 1698
Drömann, D., 891
Drouet, M.-T., 1270
Drusano, G. L., 360
Duan, L.-X., 1623
Duan, W., 1787
Dube, S., 1610
Dubois, F., 556
Duckmanton, L., 1263
Dudhane, A., 404
Duliege, A.-M., 1502
Dumler, J. S., 1835
Dumon, B., 61
Dumont, B., S55
Duong, M., 1472
Dupon, M., 1546
DuPont, H. L., 827
Dürr, F., S58
Dussaix, E., 600, 1816
Dworkin, M. S., 114
Dworkin, R. H., S76
Dwyer, D., S64
Dyer, I., 1795
Dykewicz, C. A., 636
Eaton, K. A., 1399
Eggerstedt, J. M., 1860
Egorov, A., 1359
Eijk, P P., 1067
Eing, B., 1544
Einsele, H., 1233
Eisenach, K., 1115
Eisner, W., 164
Elbeik, T., 669
Eling, W. M. C., 1225
Elkins, K. L., 611
Elkins, R., 1193
Ellner, J. J., 1115, 1861
El-Madhun, A. S., 933
El-On, J., 1081
Emery, S., 992
Emini, E. A., 360
Engle, R., 1193
Engleman, E. G., S39
English, B. K., 1122, 1649
English, R. V., 968
Enriquez, F. J., 820
Erice, A., 297, 531
Ernst, P. B., 1516
Ersbøll, A. K., 1299
Eschenbach, D., 1352
Espinel, I., 1133
Eugene, G., 600
Eugen-Olsen, J., 1334
Excler, J.-L., 1502
Fahey, J. L., 423
Falagas, M. E., 1783
Fankhauser, R. L., 1571
Fantuzzi, G., 1830
Farkas, S., 1075
Farzadegan, H., 388
Fè d'Ostiani, C., 1750

Feng, W., 1198
Fennell, C. L., 446
Fenoglio, D., 488
Fenton, T., 368
Feoli-Fonseca, J. C., 1492
Ferey, M. P., 1816
Ferko, B., 1359
Fernandes, O., 911
Fernández-Viña, M. A., 1799
Feron, E. J., 27
Ferretti, M. L., 878
Fesus, L., 1288
Fichtenbaum, C. J., 834
Fiddian, A. P., S81, 349
Fields, P. I., 460
Fikrig, E., 1198, 1512, 1835
Filho, J. O., 1856
Filion, M., 1492
Fillet, A.-M., S55
Fimbel, B., 556
Finegold, S., E1
Fischer, E. R., 1406
Fish, J. C., 1791
Fishbein, M., 1060
Fitting, C., 270
FitzGerald, G., 560
Fitzpatrick, L., 1488
Fitzpatrick, M. L., 138
Flaherty, E. E., 1707
Flavell, R. A., 1198, 1512
Fleenor, M., 1579
Fleisher, T. A., 1095
Fleuridor, R., 1213
Fleury, H. J. A., 1546
Floret, D., S58
Foote, M., 686
Forsberg, J., 274
Fortney, K. R., 191, 1684
Fotheringham, N., 1075
Fouts, T. R., 1306
Fox, L., 70
Fradin, C., 792
Fraser, D., 1081
Fraser, V. J., 1174
Freidman-Kien, A. E., 1610
Freitas, V., 1856
French, M., 992
Frey, S., 1181
Frey, T. K., 642
Freymuth, F., 600
Friedman, H. B., 45
Friedman, H. M., 1635
Friedman, J., 707
Fries, B. C., 1761
Frucht, D. M., 1095
Fugger, L., 1334
Fujimoto, J., 178
Fujisawa, J.-I., 16
Fujiwara, K., 325
Fukai, K., 325
Fukuda, K., 53
Fuller, M. D., 1821
Fulton, S. A., 1105
Furihata, K., 717
Fyfe, G., 992
Gabrielli, L., 1145
Gagnier, P., 368
Galal, H., 512
Galama, J. M. D., 256
Galli, L., 862
Gallinella, G., 1826
Galloway, D. A., 1604
Gam, A. A., 1856
Gambill, G., 1526
Gangar, M., 1177
Gao, S.-J., 846
Garcia, S., 1158
Garcia-Houchins, S., 783
Garcon, N., 1139
Garlock, K. A., 626
Garner, R. P., 1799
Garsia, R., 992
Garvy, B. A., 235
Gasnault, J., 1816
Gaudreau, A., 297
Gaudreault-Keener, M., 626
Gaydos, J. C., 1776
Gazzard, B. G., 349
Gebhard, D. H., 968
Geisbert, T., 651
Gendelman, H. E., 1000
Genital Ulcer Disease Surveillance Group, 1795
Gentilomi, G., 1826
George, L. K., S67
George, S., 1530
Gerken, G., 260
Gerrior, J., 1369
Gershon, A. A., S7, S48, S64, 539
Gershon, M. D., S7
Gerstberger, S. M., 1095
Gerstoft, J., 1334
Getz, J., 172
Ghaffari, A. M., 45
Ghezzi, M. C., 1743
Ghezzi, P., 471
Ghisetti, V., 1145
Ghorpade, A., 1000
Gibbons, L., 1783
Gibson, F. C., III, 200
Gigliotti, F., 235
Gilbert, P., 340
Gillon, J., 1779
Ginsberg, R. S., 92
Girard, W. M., 121
Gissmann, L., 252
Glass, R. I., 1571
Glenn, G., 1139
Gluckman, S. J., 92
Goebel, F. D., 854
Gold, B. D., 460
Goldberg, M., 1795
Goldblatt, E., S109
Goldstein, D., 858
Golenda, C., 1139
Gomard, E., 61
Gomes, N. A., 1847
Gomez, A., 1089
Gonzalez, A., 1457
Gonzalez, E., 1860
Good, J., 1263
Goodwin, C., 1327
Gooley, T. A., 1153
Gor, D. O., 285
Gordon, C., 1229
Gordon, S. M., 526
Gorter, A. D., 1067
Goudeau, A., 556
Goudsmit, J., 1806
Gougeon, M.-L., 1158, 1288
Goujard, C., 1816
Gouma, D. J., 883
Govindarajan, S., 1193
Graham, D. Y., 717
Graham, M. F., 1516
Grangeot-Keros, L., 600
Granoff, D. M., 870
Granström, M., 1379
Grant, S. M., 138
Grassauer, A., 1359
Green, D., 1795
Greenberg, M., 1707
Greene, W. C., 669
Grieco, V., 1352
Griffin, D. R. G., S76
Griffin, P. M., 752
Griffith, D. E., 121
Griffiths, J. K., 834, 915
Griffiths, P. D., 349
Grimaldi, G., Jr., 911
Grimm, R., 854
Groschup, M. H., 693
Grose, C., S2
Grosser, S., 423
Gruber, W. C., 1555
Grubert, T. A., 1604
Gruel, Y., 556
Guarino, A., 1373
Gubareva, L. V., 1257, 1592
Guderian, R. H., 1133
Guerois, C., 556
Guerrero, J., 820
Guess, H. A., S58
Guidet, B., 270
Guitton, C., 270
Gupta, K., 446
Gupta, R. K., 870
Gutiérrez, J., 599
Gutmann, L., 159
Gwynne, M., 368
Haaheim, L. R., 933
Habicht, G., 722
Haddad, F., 911
Hadding, U., 875
Haeffner-Cavaillon, N., 1158
Hagan, P., 289
Hahn, F., 1000
Haidaris, C. G., 235
Haist, I., 693
Haivanis, R., 1707
Hall, T., 1139
Hammer, S., 340
Hammond, R., 752
Handsfield, H. H., 1604
Hanna, B., 1047
Hansen, F., 891
Hansen, J.-E. S., 1299
Hanski, E., 147
Hanson, D. L., 114, 1126
Hao, Y., S7
Hara, J., 1244
Harmsen, A. G., 235
Harrigan, P. R., 1327
Harris, P. R., 1516
Harrison, C. R., 846
Harrison, L. H., 569
Hartung, T., 686
Harzic, M., 61
Hashemi, F. B., 1343
Hashimoto, I., 16
Hasle, H., 318
Hatheway, C. L., 172
Hay, J., S34
Hayden, F. G., 1181
Haydon, G. H., 1779
Hayes, P. C., 1779
Hayward, A. R., S95, S104, S109
He, J., 1787
Hebart, H., 1233
Heckels, J. E., 451
Hedges, S. R., 742
Heeren, T. C., 1707
Hegerich, P. A., 1193
Heimer, R., 1835
Heine, R. P., 815
Hellström, P. M., 1379
Hendricks, K. A., 172
Hermsen, C. C., 1225
Hernández-Jaúregui, P., 820
Herr, W., 260
Hertzog, P., 858
Heudebert, G. R., 921
HHV-8 Interlaboratory Collaborative Group, 304
Hiemstra, P. S., 1067
Higgins, T. J., 92
Hightower, A. W., 827
Hill, A., 1803
Hill, D., 334
Hill, E., 297, 1616
Hillier, S. L., 441
Hillyer, G. V., 560
Hinnebusch, B. J., 1406
Hirashima, N., 1185
Hirschl, A. M., 1521
Ho, D. D., 1317
Ho, H., 1075
Ho, M., 520
Hoehl, B., 294
Hoen, B., 61
Hoepelman, A. I. M., 1231
Hoesley, C., 921
Hoffman, S. L., 592
Hoffmann, M. K., 404

Hogg, R. S., 662
Holder, D. J., 360
Holland, C., 1139
Holland, S. M., 1095, 1719
Holländer, G., S99
Holmes, K. K., 1352
Holodniy, M., 80
Honigman, A., 535
Hood, A. F., 191, 1684, 1688
Hoofnagle, J. H., 1483
Hook, E. W., III, 742
Hooks, J. J., 310
Hooton, T. M., 446
Hoover, E. A., 960
Horgan, M. M., 1174
Horowitz, H. W., 404
Horsburgh, B. C., 618
Hosaka, N., 1030
Hosogaya, S., 717
Hossler, P. A., 1767
Hou, J., 1585
Hou, Z., 1047
Hovi, T., 1567
Hoxie, J., 1623
Hoy, J., 992
Hsieh, S.-Y., 866
Hu, A., 618
Hu, H.-L., 1616
Hudnall, S. D., 1791
Huggins, J., 651
Humphrey, R. W., 413
Huraux, J.-M., S55
Husman, A.-M. de R., 1806
Hutcheson, D., 1795
Hutin, Y. J. F., 904
Hutwagner, L., 752
Ibegbu, C., 680
Iino, S., 1185
IJdo, J. W., 1835
Imazeki, F., 325
International Valaciclovir HSV Study Group, 603
Inungu, J., 1229
Ioannidis, J. P. A., 349
Irving, W. L., 39
Irwin, M., S104
Israel, N. R., 460
Ito, S., 1391
Ito, Y., 1391
Ivanoff, S., 1019
Ivanyi, J., 760
Iversen, A. K. N., 1334
Jackson, D. J., 1053
Jackson, S., 983
Jacobs, D. R., Jr., 138
Jacobs, W. R., Jr., 769
Jacobson, M. A., 1446
Jadoun, J., 147
Jafri, H. S., 1526, 1555
James, V., 39
Jamieson, F. B., 1263
Jamison, R. M., 1860
Janoff, E. N., 431
Janossy, G., 1166
Janvier, G., 1019
Jarquin-González, C., 1457
Jarvis, W. R., 266, 1539
Jefferis, R., 707
Jenkins, C., 920
Jenkins, D. E., S39, 940
Jenkins, J. K., 1726
Jenny, A., 949
Jensen, T., 1334
Jenson, H. B., 846
Jhung, J. W., 1205
Jidell, E., 274
Jimenez, E., 368
Jin, X., 1317
Jitwatcharanan, K., 243
Jobe, D. A., 733
John, A., 1667
John, K., 1688
Johnson, E. A., 172
Johnson, J. L., 1115, 1861
Johnson, K. D., 569
Johnson, M., 1166
Johnson, M. A., 1327
Johnson, S., 1497
Jokinen, S., 1567
Joloba, M., 1115
Jones, G. R., 451
Jones, J. L., 114, 1126
Jones, M., S95, S109
Jones, R. B., 1713
Jordan, H. L., 503
Jouault, T., 792
Judson, F. N., 1579
Juffermans, N. P., 1839
Jurriaans, S., 1024
Juto, P., 274
Kadiltsoglou, I., 1734
Kaewvichit, R., 243
Kain, K. C., 1852
Kalish, M. L., 101
Kane, C., 1177
Kankasa, C., 1787
Kaplan, G., 580
Kaplan, J. E., 114, 1126
Kaplan, M. H., 1030
Karanja, J., 1352
Karaterki, A., 1816
Karita, M., 213
Karp, C. L., 1642
Kasahara, K., 127
Kaslow, R. A., 45
Kasper, D. L., 200, 569
Kassis, I., 535
Kasule, J., 109
Katinger, D., 1359
Katinger, H., 1359
Kato, T., 1185
Katona, L., 722
Katow, S., 642
Katsuyama, T., 717
Katz, B. P., 1684
Katzenstein, D., 109
Kaufmann, G. R., 1812
Kawabata, S., 1516
Kazanjian, P., 1530, 1767
Kazatchkine, M. D., 1158
Kee, R., 1795
Keen, M. A., 1534
Keet, I. P. M., 1024
Keith, J. C., Jr., 1205
Keith, J. M., 700
Kelleher, A. D., 1812
Keller, M., 375
Kelley, P. W., 1776
Kelsey, S. M., 1421
Kemper, C. A., 1177
Kempf, W., 841
Kerkhof-Garde, S. R., 1008
Kessler, H., 70
Kester, K. E., 1139
Kew, M. C., 1193
Keyser, E., 1526
Khamboonruang, C., 1507
Khanna, B., 460
Kimura, H., S13, 310
Kimura, T., 16
Kinchington, P. R., S16, S27
King, C. L., 512
Kirkham, C., 1667
Kirn, A., 1270
Kiviat, N. B., 1604
Kiyokawa, N., 178
Kiyono, H., 1516
Kiyosawa, K., 717
Klaskala, W., 547
Klein, M. R., 1008
Kline, B. C., 584
Kline, M. W., 776
Knapp, J. S., 1707
Knaup, R., 1795
Kobayashi, K., 127
Kobayashi, R., 318
Koedel, U., 854
Kögler, G., 544
Kohli, Y., 1391
Kokka, R., 1047
Kondo, K., 1244
Kondo, M., 1244
Kondo, Y., 1185
Korber, B. T. M., 1317
Koski, C. L., 1228
Kotzin, B. L., 70
Koup, R. A., 1163, 1317
Kourtis, A. P., 680
Koutsky, L. A., 1604
Kozel, T. R., 1464
Krakauer, T., 573
Krakowka, S., 1399
Krasinski, K., 1047
Kreiss, J. K., 441, 983, 1053, 1352
Kreiswirth, B. N., 164
Krempe, C., 544
Kremsner, P. G., 1221
Krogstad, P., 375
Krol, A., 1024
Krone, M. R., 978
Krzych, U., 1139
Kuck, K. M., S27
Kuczius, T., 693
Kühn, J. E., 1544
Kumagai, T., 717
Kumlin, U., 274
Kun, J. F. J., 1221
Kurimatsu, M., 1185
Kunkl, A., 488
Kuo, C.-H., 207
Kuppermann, B. D., 1149
Kuritzkes, D. R., 70, 1497
Kuriyama, M., 1391
Kuypers, J. M., 1604
Kwok, S., 375
Kwon, A., 1095
Kyd, J. M., 1667
Laal, S., 1534
Lacy, K. E., 92
LaDuca, J. R., 1610
LaFleur, B., S109
Lalezari, J. P., 1821
Lam, E. M., 940
Lambert, G., 101
Lambert, J. S., 598
Lambert, S. B., 954
Lammie, P. J., 827
Lamy, P. D., 1821
Lanar, D. E., 1139
Landay, A., 70, 1343
Lande, R., 466
Landesman, S., 560
Landini, M. P., 1145
Lang, W., 603
Langenberg, A. G. M., 1
Langendam, M., 397
Langston, C., 539
Lannuzel, A., 1816
Lanotte, P., 556
Lanzafame, P., 1698
Larson, A. E., 172
LaRussa, P., S48, S64
la Sala, A., 466
La Scola, B., 278
Laskus, T., 1189
Lasky, T., 1228
Lastovica, A., 460
Lau, D. T. Y., 1483
Lau, G. K. K., 1585
Lau, J., 349
Laufs, R., 1544
LaVoy, A. G., 526
Lavreys, L., 1053
Law, M., 1812
Lazzarotto, T., 1145
Leach, C. T., 846
Leal-Herrera, Y., 1089
Lebon, P., 600
Lecoeur, H., 1288
Lederman, M. M., 70
Lee, B. C., 1217
Lee, C. A., 1166
Lee, C. K., 1585
Lee, F. K., 680
Lee, K. K., 539

Lee, P., S48
Leinikki, P., 1567
Lemaire, L. C. J. M., 883
Lennette, E. T., 304
Leonard, J. M., 70
Lepidi, H., 278
Le Pogam, S., 556
Leung, K.-M., 375
Levin, M. J., S95, S104, S109
Levine, W. C., 1060, 1795
Levy, J. K., 503
Levy, J.-P., 61
Lew, J. F., 560
Lewis, J. S., 1060, 1795
Lewis, L. L., 776
Li, W., 531, 1623
Liang, R., 1585
Liang, Y.-H., 503
Liaw, Y.-F., 866
Liegler, T. J., 669
Liguory, O., 904
Lim, W. L., 1585
Lin, I., 940
Lin, J.-S. L., 1707
Linnavuori, K., 1567
Li Pira, G., 488
Lipovsky, M. M., 1231
Litchfield, B., 1795
Liu, C., 940
Livingston, L., 1122
Lloyd, A., 992
Loch, J., 431
Logan, L., 334
Lohse, A. W., 260
Lombardi, A., 1145
Looareesuwan, S., 520
Loomis-Price, L. D., 1306
Lotero, J. O., 266
Loutfy, M. R., 1852
Love, J. L., 1610
Lovrich, S. D., 733
Lowrie, R. C., Jr., 722
Lowry, P. W., 138
Ludwig, K., 1551
Ludwig, S. L., 1776
Ludwig, T. S., 138
Lungu, O., S7, S48, 539
Luty, A. J. F., 1221
Lutz, J. E., 1217
Lycett, C., 1779
Lyles, C. M., 1507
Lynch, J. A., 1040
Maartens, G., 580
Maas, J. J., 1024
MacDonald, R., 431
MacGregor, R. R., 92
Mach, M., 1233
MacKenzie, C. R., 875
Madzime, S., 109
Magder, L., 1228
Mageed, R. A., 707
Magelli, C., 1145
Magnarelli, L. A., 1835
Magpantay, L. I., 304
Mahomed, K., 109
Mainardi, J.-L., 159
Makristathis, A., 1521
Malamud, D., 1635
Malaty, H. M., 717
Maldonado, Y., 109, 334
Mallardo, G., 1373
Malley, R., 878, 1555
Mallory, S., S22
Manaresi, E., 1826
Manca, F., 488
Mancini, C., 1743
Mandal, B. K., S52
Mandaliya, K., 441, 983, 1053
Mann, D. L., 1040, 1799
Marchadier, E., 1816
Marcus, L. C., 1181
Margolick, J. B., 388, 1642
Margolis, H. S., 954, 1579
Margolis, T. P., 1149
Marianneau, P., 1270
Markham, R. B., 388, 1507
Markowitz, L., 1040
Marks, J. A., 733
Maroto, M. del C., 599
Marousek, G., 526
Marques, A. R., 1483
Marrazzo, J. M., 1604
Marrie, T., 1075
Martin, D. F., 1149
Martin, H. L., Jr., 441, 1053
Martín, J., 247
Martinez, A., 70
Martinez-Maza, O., 423
Masbar, S., 592
Mascola, J. R., 1306
Maslow, J. N., 1719
Masquelier, B., 1546
Massari, P., 1373
Mathiesen, L., 1299
Matrosovich, M. N., 1257
Matsui, S., 334
Matthews-Greer, J. M., 1860
Maurin, M., 278
Maury, E., 270
Mayaux, M. J., 600
Mayaux, M.-J., 1019
Mayer, H., 185, 1369
Mayo, M. S., 742
Mazzarello, G., 488
Mbizvo, M. T., 109
McCarville, S., 858
McClean, W., 597
McClure, E. M., 1457
McCracken, G. H., 1526
McCullers, J. A., 1592
McDermott, D. J., 551
McDonald, D. M., 1779
McIntosh, K., 560
McKenzie, R., 1483
McKinney, R. E., Jr., 776
McLean, R. G., 1457
McNeil, M. M., 1539
McQuillan, G. M., 954
McSherry, G. D., 776
Mduluza, T., 289
Meals, E., 1122
Meazza, C., 471
Medhat, A., 512
Medley, F., 577
Megiovanni, A. M., 488
Meibohm, A., 360
Meissner, H. C., 1555
Melchers, W. J. G., 256
Melo, A., 1856
Mencacci, A., 1750
Menegus, M., S64
Menotti, L., 841
Mensen, E. A. M., 1024
Merriweather, A., 282
Mertz, K. J., 1060, 1795
Meshnick, S. R., 1767
Meyer, T., 252
Michael, E. J., S27
Michael, N. L., 1306, 1799
Miedema, F., 1008, 1024
Millan-Velasco, F., 334
Miller, A. R. O., 451
Miller, R. F., 1767
Miller, R. L., 551
Miller, W. J., 531
Miner, R. C., 526, 1821
Minton, E. J., 39
Mirandola, P., 841
Mirochnick, M., 368
Misawa, K., 717
Mishori, E., 1843
Mitchell, C., 1787
Miyaji, H., 1391
Miyamura, T., 1231
Miyoshi, H., 1244
Mizokami, M., 1185
Mocroft, A., 1166
Modaí, J., 904
Mody, C. H., 803
Mofenson, L. M., 598
Mohamed, S., 512
Mohammed, K. A., 1450
Molina, J.-M., 904
Momin, P., 1139
Mommers, E., 1225
Monari, C., 1464
Monroe, S. S., 1571
Montagnoli, C., 1750
Montali, R. J., 1719
Montalvo, E. A., 846
Montaner, J. S. G., 662
Monte, R., 1698
Moodley, D., 1327
Moodley, J., 1327
Moore, J. P., 597
Moore, K. H. P., 1327
Moore, R. D., 1642
Moran, A. P., 1549
Moreno, C., 760
Morgan, B. P., 1597
Mori, C., 35
Mori, T., 178
Morikawa, S., 1231
Moriondo, M., 862
Morse, A., 1229
Morse, S. A., 243, 1060, 1707, 1795
Mortara, L., 488
Mortimer, L., 815
Mosci, P., 1750
Mosley, J. W., 1163
Moss, D. M., 827
Mostad, S. B., 983
Mottram, K., 1579
Moulton, L. H., 1562
Moura, H., 820
Movahhed, H., 1075
Moye, J., 560
Moye, J., Jr., 598
Moyer, L. A., 954, 1579
MRSA Collaborative Study Group, 164
Mubarak, K. K., 1450
Mufson, M. A., 925
Mugerwa, R. D., 1115, 1861
Mukherjee, P. P., S52
Mukherjee, R., S52
Mulamba, G. B., 618
Muldoon, M., 1317
Mulero-Marchese, R. D., 227
Müller, B., 841
Mullins, J. I., 1334
Mundy, L. M., 1174
Munjoma, M., 109
Muñoz, O., 1089
Munson, R. S., Jr., 191
Murphy, C., S52
Murphy, D. T., 121
Murphy, T. F., 1667
Murphy, T. V., 577
Murray, B. E., 1416
Murray, H. W., 908
Musiani, M., 1826
Musser, J. M., 769, 776
Muster, T., 1359
Mutapi, F., 289
Mwatha, A. K., 441
Nafeh, M., 512
Nagai, T., 35
Nagashunmugam, T., 1635
Naggan, L., 1081
Nahmias, A. J., 680
Naik, T., S52
Nakano, T., 1185
Nalin, D., 1181
Namale, A., 1115
Nang, R., 1776
Nasci, R. S., 1457
Nash, D., 1228
Nasreen, N., 1450
Nass, P. H., 611
Nathoo, K., 109
Natpratan, C., 243, 1507
Navas, S., 247
Navin, T. R., 1126
Ndebele, K., 1726

Ndhlovu, P. D., 289
Ndinya-Achola, J. O., 441, 983, 1053, 1352
Neagle, M. B., 783
Neal, K. R., 39
Nelson, K. E., 243, 1507
Nelson, S., 1075
Nesheim, S. R., 680
Nessly, M., 360
Neto, M. P.-O., 911
Neubert, U., 1676
Neva, F. A., 1856
Newcomb, F. M., 413
Newell, M., 858
Newhall, W. J., 1707
Newland, A. C., 1421
Newman, C., 1122
New York City Perinatal HIV Transmission Collaborative Study Group, 101
Nickey, L. N., 172
Niebler, B., 1359
Nielsen, J. O., 1299
Nielsen, S. D., 1299
Nishanian, P., 423
Nishikawa, M., 16
Nitayaphan, S., 1040
Niu, M. T., 80
Nixon, D. F., 1317
Noel, G. J., 1095
Noel, J. S., 1571
Normark, S., 1379
Nottet, H. S. L. M., 1279
Novotny, J., 1795
Nsubuga, P., 1861
Nuessle, S., 1821
Nutman, T. B., 1133
Nyange, P., 983
Nyange, P. M., 441, 1053
Ochs, H. D., 318
Ockenhouse, C. F., 1139
O'Donnell, J. A., 1795
Offenstadt, G., 270
Offerdahl, M. R., 138
Ogura, K., 127
Okada, S., 1244
Okhuysen, P. C., 827
Okwera, A., 1861
Old, M., 334
Oligny, L. L., 1492
Olivier, M., 1472
Olofsson, J., 933
Olsen, K., 1526
Olson, J. K., S2
Omata, M., 325
Opal, S. M., 1205
Operskalski, E. A., 1163
Opstad, N., 431
Orazi, A., 1688
Orendi, J. M., 1279
Orle, K. A., 1060
Orlikowsky, T., 404
Orman, K. L., 1649
O'Shaughnessy, M. V., 662
Osterhaus, D. M. E., 27
Osugi, Y., 1244
Ota, H., 717
Ottinger, J., 1170
Ouellet, N., 1472
Overbaugh, J., 983, 1060
Owens, M., 858
Oxman, M. N., S104
Oyaizu, N., 1030
Ozeri, V., 147
Pahwa, S., 1030
Pakker, N. G., 1008
Palardy, J. E., 1205
Palazzetti, B., 1464
Palmer, K. L., 191, 1688
Palumbo, P., 680
Pan, X., 776
Pan, Z.-J., 220
Panagiotidis, C. A., S7
Panteliadis, C., 1734
Papaevangelou, V., 1047
Pappagianis, D., 1217
Paradise, M., 978
Paredes, W., 1133
Parejo, N. A., 1205
Parenti, D. M., 526, 1181
Parrish, S., 858
Pastor, P., 577
Pasvol, G., 760
Patel, P., 1526
Patel, R., 584
Patterson, J. E., 577
Paul, R., 854
Paunio, M., 1567
Pav, J., 368
Pavia, A. T., 349
Pediatric AIDS Clinical Trials Group protocol 250 Team, 368
Pedral-Sampaio, D., 1488
Peiper, S. C., 1623
Peiris, M., 1250
Pellegrin, I., 61
Pellegrin, J.-L., 1546
Peltola, H., 1567
Perez-Perez, G., 1089
Perkin, R. T., S1
Perkins, B. A., 1457
Perkins, M., 1115
Perno, C.-F., 413
Perry, M., 460
Persidsky, Y., 1000
Persson, K., 274
Pesnicak, L., 310
Petric, M., 1263
Petrofsky, M., 896
Petroni, G. R., 1170
Pettinelli, C., 1170
Pettus, K. S., 1795
Peyrieux, J.-C., S58
Pfister, H.-W., 854
Philipp, M. T., 722
Phillips, A. N., 1166
Phillips, M., 1115
Phillips, T. M., 1719
Phung, D., S76
Piédrola, G., 599
Pieniazek, N. J., 820
Pieper, C. F., S67
Pierson, C., 478
Piesman, J., 722
Pietrella, D., 1464
Pikis, A., 700
Pillay, K., 1327
Piper, K. E., 584
Pirmez, C., 911
Pirofski, L.-A., 707, 1213
Pitha-Rowe, I. F., 1095
Pitrak, D. L., 686
Pitt, J., 560
Plaeger, S., 375
Plotkin, S. A., S58
Plum, G., 1209
Plumb, R., 1327
Poiesz, B. J., 1610
Polissar, N. L., 1
Pollack, H., 1047
Pomerantz, R. J., 1623
Pontesilli, O., 1008
Porat, N., 1081, 1843
Potena, L., 1145
Poulain, D., 792
Pradelli, P., 1145
Preas, H. L., 887
Prendergast, M. M., 1549
Presterl, E., 1521
Preston, D., 1547
Prince, G. A., 925
Protzer, U., 260
Puren, A. J., 1830
Puri, A. K. G., 431
Putnam, S. D., 1202
Qin, X., 1416
Quadrifoglio, F., 1698
Quinn, T. C., 1642
Quiroga, J. A., 247
Rabkin, C. S., 304
Race, R., 949
Radkowski, M., 1189
Rady, P. L., 1791
Ragnaud, J.-M., 1546
Rakela, J., 1189
Ramey, R. R., II, 1497
Ramilo, O., 1555
Ramos, E., 1434
Raoult, D., 278
Raponi, G., 1743
Rappuoli, R., 1373
Raudonikiene, A., 220
Ray, B., 752
Razeghi, P., 1830
Redd, S. C., 636
Redfield, R. R., 1306
Redman, R. L., 940
Reed, C., 1217
Reef, S. E., 636
Reeves, M. W., 266
Regueira, M., 266
Reid, B. S., 539
Reilly, M., 983, 1352
Reinhard, J., Jr., 1000
Reitano, M., 603
Rekrut, K., S64
Rentier, B., S43
Resti, M., 862
Retini, C., 1464
Reynolds, J., 1795
Rhone, S. A., 662
Rice, P. A., 1707
Rice, R. J., 1707
Rich, E. A., 1434
Richardson, B. A., 441, 1053
Richwald, G. A., 1795
Ries, A. A., 172
Rigau-Pérez, J. G., 1457
Rincón, M., 1512
Ringler, S. S., 1399
Rippere, K., 584
Ritchey, J. W., 503
River, M. E., 1217
Rivière, Y., 1019
Robb, M. D., 1040
Robb, M. L., 1306
Roberts, C. G. P., 1317
Roberts, D. D., 497
Roberts, E. D., 722
Roberts, M. S., S85
Roberts, P. L., 446
Roberts, R. B., 164
Roberts, T., 1228
Roberts, T. C., 626
Robinson, J. M., 603
Rochford, G., 1047
Rodrigues, R. G., 497
Rodriguez, W. J., 700
Rodriguez-Barradas, M. C., 707
Rodriguez-Panadero, F., 1450
Roebuck, K. A., 1343
Rogers, A. B., 960
Rogers, B. B., 1526
Rogers, P. D., 1726
Roilides, E., 589, 1734
Roivainen, M., 1567
Rokita, E., 1521
Romani, L., 1750
Romanova, J., 1359
Roodman, G. D., 846
Roos, M. T. L., 1024
Root, R., 1075
Rosen, D., 318
Rosenblatt, H., 560
Rosenthal, P. J., 285
Ross, J. G., 526
Rossi, M. E., 862
Rotter, M. L., 1521
Rottman, J. B., 503
Rousseau, F., 70
Rousselle, J. C., 733
Routray, S., 850
Roux, A., 1158
Rouzioux, C., 1019
Rowe, B., 920
Royaltey, S. S., 1217

Royer, C., 1270
Rubins, J. B., 431
Rubio, C., 1379
Rubocki, R., 1000
Rudin, C., S99
Ruiz, N., 1799
Russell, M. W., 742
Russo, P. A., 1492
Rust, C., 1676
Rutledge, J. C., 318
Ruyechan, W., S34
Rybkine, T., 159
Ryder, P. L., 1579
Saag, M. S., 349
Saah, A. J., 45
Saba, J., 1327
Sabin, C. A., 1166
Sada, E., 1434
Saddier, P., S58
Sadzot-Delvaux, C., S43
St. Clair, M., 70
St. Louis, M. E., 1060, 1795
Saisho, H., 325
Saladino, R. A., 878
Salazar-Gonzalez, J. F., 423
Samanich, K. M., 1534
Samanta, S., 1512
Sanchez, P. J., 1555
Santoro, M. G., 564
Santos, R. A., S2
Santosham, M., 1562
Sapan, C. V., 1040
Sarafian, S. K., 1707
Sarfati, C., 904
Sasaki, M., 1185
Sato, I., 127
Sato, N., 178
Sauerwein, R. W., 1225
Schaaf, B., 891
Schachter, J., 1202
Schacker, T., 1616
Schäfer, P., 1544
Schaufele, R., 589
Schechter, M., 1488
Schechter, M. T., 662
Scheid, A., 544
Schell, R. F., 733
Schellekens, P. T. A., 1024
Schluter, W. W., 636
Schmader, K., S67
Schmaljohn, C., 651
Schmidt, C., 1233
Schnittman, S. M., 80
Schnitzler, M. A., 626
Schnizlein-Bick, C. T., 1688
Schnurr, D. P., 1776
Schoen, R. T., 1198
Schoenbaum, E. E., 101
Schollaardt, T., 520
Schonberger, L. B., 53
Schonfeld, T., 535
Schooley, R. T., 1488
Schoppel, K., 1233
Schröder, S., 252
Schröter, M., 1544
Schubach, A., 911
Schuitemaker, H., 397, 1008, 1806
Schulz, T. F., 304
Schwan, T. G., 1406
Schwander, S. K., 1434
Schwartz, D. A., 820
Schwebke, J., 1795
Schwenk, R., 1139
Sei, C., 717
Sein, T., 589
Sekulovich, R. E., 1, 8
Sela, S., 147
Senaldi, G., 471
Sepulveda, J., 334
Sereni, D., 61
Severina, E. P., 164
Seyama, K., 318
Sha, B. E., 1343
Shafer, M.-A., 1202
Shaffer, R. A., 1202
Shah, K. V., 45
Shaklee, C. L., 471
Shapiro, C. N., 1579
Shapiro, R. L., 752
Shatzen, E. M., 686
Shaughnessy, M., 1
Shehata, M., 512
Shelton, S., 1526
Shen, L.-P., 423
Shenep, J. L., 1649
Sheppard, H. W., 1306
Sherlock, C., 662
Sherman, M. E., 45
Shieh, W.-J., 1457
Shimizu, T., 717
Shopsin, B., 164
Shuer, L. M., 1217
Shugarts, D., 1497
Shukla, S., S71, S81
Sibley, D. A., 742
Sieck, T. G., 227
Sieczkowski, L., 547
Sierra, J., 1434
Silbart, L. K., 850
Silverstein, S., S48, 539
Simard, M., 1472
Siminski, S., 368
Simmonds, P., 1779
Simonds, R. J., 680
Simonsen, L., 53
Sinei, S., 1352
Singer, G. G., 626
Singh, K. V., 1416
Sjölund, A., 760
Skinhøj, P., 1334
Skutelsky, E., 147
Slade, H. B., 551
Slaoui, M., 1139
Slonim, A., 1843
Smillie, D., 39
Smith, H. R., 920
Smith, J. W., 1767
Smith, K. J., S85
Smith, M. H., 551
Smith, N. H., 900
Smith, P. D., 1516
Snape, S., 520
Snippe, H., 1279
Snydman, D. R., 1783
Sobel, R. A., 1217
Söderberg, S., 274
Solomon, H. M., 172
Sombardier, M.-N., 904
Sommer, M., S22
Sonnenberg, M. G., 1534
Sordillo, E. M., 294
Søreide, A., 933
Sorensen, K. N., 1217
Sosa, C., 547
Soto, R., 547
Sougakoff, W., 159
Spear, G. T., 1343
Spear, P. G., 8
Spector, S. A., 368, 922
Speelman, P., 1839
Sperling, M., 1181
Sperling, R. S., 368
Spezzacatena, P., 1145
Spicer, J. T., 289
Spiegel, R. A., 1457
Spijkerman, I., 397
Spiller, O. B., 1597
Spinola, S. M., 191, 1684, 1688
Sporer, B., 854
Spritzler, J., 70
Spruance, S. L., 349
Spurrell, J. C. L., 803
Staat, M. A., 1562
Stack, A. M., 878
Stamm, W. E., 446, 1352
Standiford, H. C., 80
Stanley, M. A., 551
Stapleton, A. E., 446
Starkey, W. G., 642
Steckelberg, J. M., 584
Steffan, A.-M., 1270
Stein, D. S., 360
Steinberg, S., S48, S64
Steketee, R. W., 101
Sternhell, K. E., 626
Stevens, C. E., 441
Stevens, D. A., 1217
Stewart, G., 992
Steyn, L., 580
Stiehm, E. R., 375
Stine, K., 1604
Stinson, D. L., S104, S109
Stockfleth, E., 252
Stone, C., 1327
Stoner, B. P., 1174
Storch, G. A., 626
Stoute, J. A., 1139
Straus, S. E., S13, 310, 1483
Stricker, R., 600
Su, B., 1379
Su, W.-W., 220
Su, X.-H., 1707
Subianto, B., 592
Suffredini, A. F., 887
Sugiura, K., 16
Sulkowski, M. S., 1642
Sullender, W. M., 925
Sullivan, J. L., 368
Sun, P., 1139
Suntharasamai, P., 520
Superti, F., 564
Supran, S. E., 1783
Suto, H., 1391
Sutton, D., 949
Suzuki, K., 1231
Swanson, D. S., 776
Swindells, S., 1000
Sydney Primary HIV Infection Study Group, 1812
Szondy, Z., 1288
Tabet, S. R., 978
Tagawa, M., 325
Taguchi, T., 178
Takahara, R., 35
Takahashi, M., 35
Takeda, T., 178
Takeuchi, H., 127
Talati, A. J., 1122
Tamaki, K., 1231
Tanaka, E., 717
Tanaka, Y., 1185
Tanaka-Taya, K., 1244
Tang, J.-H., 866
Taoufik, Y., 1816
Tapia-Conyer, R., 1089
Tary-Lehmann, M., 1434
Tauxe, R. V., 752
Taylor, A. P., 908
Taylor, J., 423
Taylor, J. P., 172
Teglas, J. P., 1019
Teixeira, L., 1115
Telford, J., 1373
Tellier, R., 1193
Tenschert, W., 1544
Terhune, S. S., 8
Terranova, M. P., 488
Thea, D. M., 101, 680
Therasse, D., 1547
Thoelen, S., 1181
Thomas, P. A., 101
Thomas, R. J., 1202
Thoming, C., 603
Thompson, C. H., 1230
Thompson, C. M., 878
Thompson, R., 1856
Thompson, S., 752
Thornton, A. C., 191, 1684
Thylin, M., 1000
Tinari, A., 564
Tirtokusumo, S., 592
Todd, K. D., 1684
Toé, L., 282
Tomai, M. A., 551
Tomasz, A., 164

Tomkinson, E., 858
Tompkins, M. B., 503, 968
Tompkins, W. A. F., 503, 968
Toossi, Z. T., 1105
Toriyama, T., 35
Torres, J., 1089
Torres, M., 1434
Totten, P. A., 1060
Towle, C., 1776
Trannoy, E., S99
Trees, D., 1795
Trent Hepatitis C Virus Study Group, 39
Trevejo, R. T., 1457
Trinel, P.-A., 792
Tsaparidou, S., 1734
Tse, C. Y. C., 1250
Tsuboi, K., 16
Turck, M., E1
Turner, C. M. R., 289
Turse, S. E., S16
Tyler, D. L., 1170
Tyring, S. K., 551, 603, 1791
Tytgat, G. N. J., 220
Tzianabos, A. O., 200
Tzipori, S., 834
Uchida, H., 178
Ueda, R., 1185
Ueda, Y., 1231
Ugen, K. E., 92
Uhl, J. R., 584
Underwood, J. C. E., 39
Unnasch, T. R., 282
Urbani, F., 466
Ussery, X. T., 539
Uyama, M., 16
Valdespino, J. L., 334
Valdez, L. M., 900
Valle, M., 1567
Valle, M. T., 488
van Alphen, L., 1067
VanCott, T. C., 1306
VanDamme, P., 1181
van der Ende, A., 220
van der Hulst, R. W. M., 220
Van der Lelij, A., 27
Van Der Pol, B., 1713
van der Poll, T., 883, 1839
van Deutekom, H., 1839
van Deventer, S. J. H., 883, 1839
van de Wiel, T., 1225
van Elden, L. J. R., 1231
Van Kruiningen, H. J., 850
van Lanschot, J. B., 883
van Leeuwen, R., 1327
van Rij, R. P., 1806
van Wetering, S., 1067
Varani, S., 1145
Vargas, H., 1189
Vassal, T., 270
Vázquez-Torres, A., 478
Vecchiarelli, A., 1464
Veenstra, J., 1024
Venet, A., 61
Venturoli, S., 1826
Verbon, A., 1839
Verhoef, J., 1279
Verjans, G. M. G. M., 27
Vernacchio, L., 1555
Verral, S. C., 686
Vesterhus, P., 1095
Vibrio Working Group, 752
Vierucci, A., 862
Villa, P., 471
Villanueba, E., S95
Vink, P., 680
Visse, B., S55
Visser, M. R., 1279
Visvesvara, G. S., 820
Vittinghoff, E., 669
Vizzard, J., 1812
Vlahov, D., 388, 1507
von Grünberg, P. W. R., 1209
Vordermeier, H. M., 760
Wade, M., 70
Wadell, G., 274
Wagner, R. D., 478
Wahl, S., 1334
Wahren, B., 1306
Wakefield, A. E., 1767
Wald, A., 978
Waldenström, A., 274
Walenkamp, A. M. E., 1231
Walker, B. D., 1317
Walker, D. J., 1767
Walker, E. S., 1843
Wallace, R. J., Jr., 121
Wallis, R. S., 1115, 1434, 1861
Walsh, T. J., 497, 589, 1734
Wang, E. E. L., 1263
Wang, H.-J., 207
Wang, L.-F., 1189
Wang, W.-C., 207
Wang, Y., 310
Wang, Z., S7, 388, 1507
Wang, Z. Q., 404
Wanke, C. A., 185, 1369
Ward, J. W., 114
Ward, M. J., 1450
Ward, R. L., 1562
Warner, T., 478
Washington, C. D., 1860
Watanabe, T., 1231
Watson, C. P. N., S91
Watson, D. A., 185
Weaver, S. C., 642
Webb, R. M., 1060
Weber, D. J., S58
Weber, R., 185
Webster, R. G., 1257, 1592
Weedon, J., 101
Weinberg, A., S95
Weiner, D. B., 92
Weinhold, K. J., 1170
Weinstein, A., 404
Weinstock, G. M., 1416
Weir, J. P., 611
Weisfuse, I., 1795
Weiss, J. B., 243, 1060, 1795
Weiss, L., 1158
Wellde, B. T., 1139
Wendel, A., 686
Wenger, P. N., 1539
Wenzel, R. P., 917
Werner, B. G., 1783
Wernet, P., 544
Wertz, G. W., 925
Wessels, M. R., 569
Wey, N., 841
Weyant, R. S., 1457
Whalen, C. C., 1861
Whitby, D., 304
White, A. C., Jr., 900
White, K., 1139
White, N. J., 520
Whitley, R. J., S71
Wick, M., 854
Widmer, G., 834
Wieneke, C. A., 733
Wignall, F. S., 1202
Wijnholds, F.-J., 1279
Wilkinson, D. A., 1163
Wilkinson, K. A., 760
Wilkinson, R. J., 760
Williams, D., 1115
Williams, H., S104
Williams, M. A., 1421
Williams, P. L., 1217
Williams, R., 1585
Williams, R. K., S13, 310
Wilson, J., 1075
Wilson, M. E., 1847
Wilson, S., 752
Wilson, S. L., 1658
Winchell, J. M., 850
Wirtz, R. A., 1139
Witebsky, F. G., 1719
Withington, S., 1421
Wolf, D. G., 535
Wölfel, T., 260
Wolitz, R. A., 1149
Wolski, K., 1115
Women and Infants Transmission Study, 560
Wong, D. C., 1193
Wood, C., 547, 1787
Wood, C. J., 803
Wood, M. J., S81
Woolhouse, M. E. J., 289
Worley, M., 1719
Worm, A.-M., 603
Wortmann, G., 1139
Wu, M., 896
Wu, M. H., 547
Wubbel, L., 1526
Xiao, S.-D., 220
Xie, C., 1713
Xu, S., 1502
Yagita, H., 1030
Yagupsky, P., 1548, 1843
Yajko, D. M., 1446
Yamanishi, K., 35, S64, 1244
Yamazaki, Y., 1391
Yan, S., 497
Yaniv, I., 535
Yao, Y., 1217
Yap, P. L., 1779
Yarchoan, R., 413
Yasuda, K., 1185
Yasukawa, L. L., S39
Yeh, A. A. M., 207
Yeh, C.-T., 866
Yip, B., 662
Yogev, R., 368, 776
Yokosuka, O., 325
Yonemoto, W., 669
Yoshitake, H., S34
Yotov, W. V., 1492
Youle, M. S., 349
Young, B., 1497
Young, L. D., 1205
Young, L. S., 896
Young, R. K., 1497
Yousten, A. A., 584
Yu, X.-F., 388, 1507
Yuen, S. T., 1585
Yuki, N., 1550
Zaki, S. R., 1457
Zaunders, J., 1812
Zbinden, R., 185
Zeckel, M. L., 1547
Zeh, J., 1616
Zerbe, G. O., S109
Zerbini, M., 1826
Zhang, X.-q., 1488
Zhao, S.-F., 1623
Zheng, J., 1000
Zheng, R., 769
Zhong, Z., 1213
Zhu, Z., S7
Zijenah, L., 109
Zolla-Pazner, S., 1502, 1534
zum Büschenfelde, K.-H. M., 260

# Subject Index


Abdomen, sepsis in, rat model, 200
Abscess
  abdominal, rat model, 200
  tubo-ovarian, in HIV infection, 1352
Acid tolerance, *Helicobacter pylori*, 213
*Acinetobacter baumannii*, bacteremia, in hemodialysis, 783
Acquired immunodeficiency syndrome (*See* Human immunodeficiency virus infection)
Acrodermatitis chronica atrophicans, in Lyme disease, *Borrelia burgdorferi* outer surface protein antibody response in, 1676
Acyclovir
  for cytomegalovirus infections, prophylactic, in bone marrow transplantation, 1153
  for herpes simplex virus infections, recurrent, 603
  for herpes zoster, S81
  for HIV infection, 349
  resistance to, herpes simplex virus, 297, 618
Adenoviruses
  antibodies, serotypes 4 and 7, epidemiology, military population, 1776
  infections, after measles-mumps-rubella vaccination, simulating vaccine failure, 1567
Adherence
  *Haemophilus influenzae*, to lung epithelial cells, defensins in, 1067
  *Helicobacter pylori*, Lewis antigen–independent, 1379
  yeasts, to fibronectin, hemoglobin effects on, 497
Adhesion molecules, in *Listeria monocytogenes* infections, 1658
Adolescents, HIV infection in, *Pneumocystis carinii* pneumonia infections with, risk factors for, 1126
Adult worm antigens, *Schistosoma haematobium*, in interleukin production, 512
Age
  vs. herpes zoster persistent pain, S71, S76
  vs. influenza mortality, 53
  vs. malaria susceptibility, 592
  vs. *Schistosoma haemobium* immune response, 289
Agglutinin, salivary, in HIV inhibition, 1635
AIDS (*See* Human immunodeficiency virus infection)
Alcohol use, inflammation in, granulocyte colony-stimulating factor and, 891
Alveolar macrophages, response to *Mycobacterium tuberculosis* antigens, in active tuberculosis, 1434
Amphotericin B, in cytokine gene activation, 1726
Analgesia, in herpes zoster, S91
Anemia, parvovirus B19–induced, in X-linked hyper-IgM syndrome, 318
Anergy
  in HIV infection, vs. CD4 T cell function, 1024
  monocyte, in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 1421
Animal models
  abdominal sepsis, rat, 200
  *Aspergillus fumigatus* inflammatory response, mouse, 1472
  *Borrelia burgdorferi* antibody production, mouse, 733
  bovine spongiform encephalopathy, mouse, 693
  candidiasis, mouse, 478
  cerebral malaria convulsions, mouse, 1225
  coccidioidal meningoencephalitis, rabbit, 1217
  cryptococcosis, mouse, 1213
  *Cryptococcus neoformans* virulence, in HIV infection, mouse, 1761
  Ebola hemorrhagic fever prophylaxis, mouse, 651
  *Encephalitozoon intestinalis* infections, nonohumans, 820
  *Enterococcus faecalis* mutants and peritonitis, mouse, 1416
  *Helicobacter pylori* vaccination, pig, 1399
  hepatitis C, chimpanzee, 1193
  herpes simplex virus type 1
    acyclovir-resistant, mouse, 618
    T cell response to, granulocyte-macrophage colony-stimulating factor production, rat, 16
    vaccination, mouse, 611
  HIV, cat, 503
  HIV vaccination
    cat, 960
    mouse, 1359
    rabbit, 850
  influenza virus A/HongKong/156/97 characterization, mouse, 1592
  *Leishmania chagasi* infections, mouse, 1847
  leishmaniasis, visceral, mouse, 908
  Lyme disease
    arthritis, mouse, 1512
    neuroborreliosis pathogenesis, rhesus monkey, 722
  *Moraxella catarrhalis* vaccination, mouse, 1667
  mucosal immunity in aspergillosis, mouse, 1750
  *Mycobacterium avium* complex infections
    mouse, 896
    tree kangaroo, 1719
  *Mycoplasma pneumoniae* pneumonia pathogenesis, mouse, 1526
  nitric oxide synthase and nitric oxide production, pneumococci in, mouse, 1649
  pneumococcal colonization, anticapsular polysaccharide antibodies and, rat, 878
  *Pneumocystis carinii* pneumonia, antigens in, mouse, 235
  polymicrobial peritonitis and sepsis, granulocyte colony-stimulating factor in, mouse, 471
  *Pseudomonas aeruginosa* sepsis, rat, 1205
  Q fever endocarditis, guinea pig, 278
  respiratory syncytial virus diversity, rat, 925
  vaginal candidiasis immunization, mouse, 227
  varicella-zoster virus
    latency, rat, S48
    uveitis, guinea pig, 310
Anorectum
  herpes simplex virus infections
    in HIV infection, 1616
    shedding in, 978
  human papillomavirus infections, treatment, 551
  squamous intraepithelial lesions, in HIV infection, in homosexual men, 45
Antibiotics (*See also specific antibiotics*)
  attributable mortality and, 917
  granulocyte colony-stimulating factor with
    for pneumonia, 1075
    for polymicrobial peritonitis and sepsis, mouse model, 471
  resistance to (*See* Drug resistance)
  susceptibility testing
    cytomegalovirus, 1821
    ganciclovir, 531
Antibody(ies)
  *Borrelia burgdorferi*, outer surface proteins, 1676
    mouse model, 733
  capsular polysaccharides, pneumococcal colonization and, rat model,

878
*Cryptosporidium*, 827
cytomegalovirus
acquisition, in transplantation, 1145
kinetics, in bone marrow transplantation, 1233
feline immunodeficiency virus, 968
hepatitis C virus, in hemophilia, 556
herpes simplex virus type 2, cervical, 1
HIV
gp120 protein, in vaccination, 92
human herpesvirus 8
epidemiology
Brazil and Colorado, 1488
Zambia, 1787
in multiple myeloma, 846
in mucosal vaccination, mouse model, 1359
lymphocyte-reactive, in HIV infection, in T cell depletion, 404
measles virus, in HIV infection, 1177
monoclonal
in convulsion prevention, in *Plasmodium berghei* cerebral malaria, mouse model, 1225
in cryptococcosis, mouse model, 1213
*Neisseria gonorrhoeae*, in concomitant infections, 742
*Neisseria meningitidis*, in vaccination, immunologic refractoriness in, 870
neutralizing, in HIV vaccination, 1502
streptococci, group B, in bacteremia, 569
*Streptococcus pneumoniae*, in vaccination response, molecular structure, 707
varicella-zoster virus, 940
Antibody-dependent cellular cytotoxicity, HIV, 1306
Antidepressants, for herpes zoster, S91
Antigens
*Bordetella pertussis*, cellular immune response to, 466
*Candida albicans*, in HIV infection, cellular immune response to, 488
*Cryptosporidium*, antibody response to, 827
cytomegalovirus
in bone marrow transplantation, prophylactic therapy for, 1153
persistent, in transplantation, 1145
HIV, CD8 T cells responsive to, quantification, 260
human herpesvirus 7, persistence in normal tissues, 841
Lewis, *Helicobacter pylori* cell binding independent, 1379
*Mycobacterium tuberculosis*
alveolar lymphocyte response to, in active tuberculosis, 1434
antibodies to, investigation for serologic diagnosis, 1534
in sputum, prognosis and, 1115
*Plasmodium falciparum*, cysteine protease-related, humoral immune response to, 285
*Pneumocystis carinii*, mouse model, 235
respiratory syncytial virus, diversity, rat model, 925
*Schistosoma haematobium* adult worm, in interleukin production, 512
T cells, for proliferation, human imm 1279
Antiinflammatory drugs, leptin levels and, 887
Antiretroviral agents, for HIV infection (*See also specific agents*)
HAART (*See* HAART (highly active retroviral therapy))
response to, 662
viral RNA level monitoring in, 1803
Antisera, Ebola virus, mouse model, 651
Apoptosis
hepatocytes, in dengue fever, 1270
monocytes, granulocyte-macrophage colony-stimulating factor effects on, in sepsis, 1421
neutrophils, inhibition, granulocyte colony-stimulating factor in, 891
renal tubular epithelial cells, *Escherichia coli* Shiga toxin in, 178
T cells, in HIV infection
Fas and Fas ligand in, 1030
nonprogressive, 669
retinoic acid inhibition, 1288
Arthritis, Lyme
*Borrelia burgdorferi* gene expression during, vs. erythema migrans, 1198
*Borrelia burgdorferi* outer surface protein antibody response in, 1676
mouse model, 1512
Asian influenza (1957–1958), epidemiology, mortality in, 53
Aspergillosis
in HIV infection, viral load in, 1642
mucosal immune response in, mouse model, 1750
*Aspergillus fumigatus*, inflammatory response to, mouse model, 1472
Astroviruses, infections, epidemiology, Mayan Mexicans, 334
Atherosclerosis
*Chlamydia pneumoniae* in, 274
cytomegalovirus in, 1860
Atovaquone, for *Pneumocystis carinii* infection prophylaxis, failure, 1767
Attributable mortality, in antibiotic therapy, 917
Azithromycin
for cryptosporidiosis, in HIV infection, 900, 915
for *Mycobacterium avium* complex infections, 121
with HIV infection, 1446

B cells
in peripheral nerves, in Lyme disease, rhesus monkey model, 722
response to HIV-1, in antiretroviral triple therapy, 70
Bacille Calmette-Guérin, vaccination
percutaneous, cellular immune response, 138
T cell repertoire in, 760
*Bacillus popilliae*, resistance in, vancomycin, 584
Bacteremia
gram-negative, treatment, endotoxemia in, 270
in hemodialysis, outbreak, 783
in HIV infection, viral load in, 1642
*Mycobacterium avium* complex, with HIV infection, treatment, 1446
streptococci group B, antibody responses in, 569
*Vibrio vulnificus*, epidemiology, oyster harvesting season, 752
Bacterial vaginosis
mucosal immune system impairment in, 1698
nonoxynol-9 effects on, 441
Bactericidal/permeability-increasing protein, in tuberculosis, 1839
*Bacteroides fragilis*, polysaccharide, for abdominal sepsis, rat model, 200
Baculovirus, in varicella-zoster virus glycoprotein expression, S13
Barrett's esophagus, in congenital varicella-zoster virus infection, 539
Blood, feline immunodeficiency virus in, 960
Blood-brain barrier, permeability
in HIV infection, metalloproteinases in, 854
in *Plasmodium berghei* cerebral malaria, mouse model, 1225
Bone marrow transplantation
cytomegalovirus infections in
antibody kinetics, 1233
ganciclovir susceptibility, 531
monitoring for, in pediatric patients, 1244
prophylaxis, 1153
hepatitis B virus clearance after, 1585
herpes simplex virus infections in, type 1, acyclovir-resistant, 618
*Bordetella pertussis*, vaccination, cellular immune response in, 466
*Borrelia burgdorferi* (*See also* Lyme disease)

antibodies to, outer surface protein C, mouse model, 733
gene expression, during erythema migrans vs. arthritis, 1198
Botulism, epidemiology, Texas, 172
Bovine spongiform encephalopathy
strain variations, molecular analysis, 693
transmission, 949
Bovine surfactant, in tumor necrosis factor-α suppression, genital mycoplasmas and, 1122
Brain, microvascular endothelial cells, activation in *Listeria monocytogenes* infections, 1658
Bronchiolitis, respiratory syncytial virus, treatment, monoclonal antibodies, 1555
Bubonic plague, transmission, by blocked fleas, *Yersinia pestis* plasminogen activator and, 1406

*cagA* gene, *Helicobacter pylori*, acid tolerance and, 213
*Campylobacter*
diarrhea, Israeli Bedouin infants, 1081
infections, Guillain-Barré syndrome in, economic costs, 1228
*Campylobacter jejuni*, infections, Guillain-Barré syndrome in, 1549
Cancer
cervical, human papillomavirus in, 252
chemotherapy for, hepatosplenic candidiasis in, interleukin-10 in, 589
*Candida*
fibronectin binding to, hemoglobin effects on, 497
fungemia, in hemodialysis, 783
*Candida albicans*
in CD4 expression on monocytes, 1464
macrophage interactions with, 792
phagocytosis, interleukin-10 effects on, 1734
in tumor necrosis factor-α production, 1734
Candidiasis
hepatosplenic, interleukin-10 in, 589
in HIV infection, 114
cellular immune response in, 488
susceptibility to, mouse model, 478
vaginal
HIV, transmission risk and, 1053
vaccination, mouse model, 227
Capsular polysaccharides, antibodies to, pneumococcal colonization and, rat model, 878
Cardiomyopathy, dilated, enterovirus infection testing in, 256
Cardiovascular disorders
*Chlamydia pneumoniae* in, 274
cytomegalovirus in, 1860
Caspase-3, measurement, in HIV infection nonprogressors, 669
CCR2 (chemokine receptor 2), mutations, HIV syncytium-inducing variant and, 1806
CCR2B (chemokine receptor 2B), in cervical secretions, in human immunodeficiency virus infection, 1334
CCR5 (chemokine receptor 5)
in HIV infection
in cervical secretions, 1334
progression and, 1019, 1163, 1306
of stem cells, 1623
mutations, 1019
CD4 molecule (*See also* T cells, CD4)
in acute infections, in HIV infection, 1642
monoclonal antibodies to, in convulsion prevention, in *Plasmodium berghei* cerebral malaria, mouse model, 1225
on monocytes, organisms regulating, 1464
CD8 molecule (*See also* T cells, CD8)
in acute infections, in HIV infection, 1642
monoclonal antibodies to, in convulsion prevention, in *Plasmodium berghei* cerebral malaria, mouse model, 1225
CD14 molecule, soluble, in tuberculosis, 1839
*CD40L* gene, mutations, in X-linked hyper-IgM syndrome, 318
CD71 molecule, depression, in septic shock, 1421
CD152 molecule (CTLA-4), blockade, in *Leishmania chagasi* infections, mouse model, 1847
Cefaclor, for otitis media, 1547
Cefuroxime, for otitis media, 1547
Cell culture, herpes simplex virus type 2, 8
Cellular immune response (*see also* T cells)
to bacille Calmette-Guérin vaccination, 138
to *Bordetella pertussis* vaccination, 466
to *Candida albicans*, in HIV infection, 488
to herpes simplex virus type 1, granulocyte-macrophage colony-stimulating factor production in, rat model, 16
to *Mycobacterium avium* complex, tree kangaroo model, 1719
to tetanus vaccination in onchocerciasis, 1133
to varicella-zoster virus, S95
dendritic cell assay for, S39
in depression, S104
IE 63 protein in, S43
in vaccination of older adults, S99
Cellulitis, in HIV infection, viral load in, 1642
Cerebral malaria, convulsions in, mouse model, 1225
Cerebrospinal fluid
JC virus in, in progressive multifocal leukoencephalopathy prognosis, 1816
metalloproteinases in, in HIV infection, 854
Cerebrospinal vasculitis, *Coccidioides immitis*, rabbit model, 1217
Cervix
herpes simplex virus type 2 antibodies in, after vaccination, 1
intraepithelial neoplasia, in human papillomavirus infections, 1604
*Neisseria gonorrhoeae* infections, immune responses in, in concomitant infections, 742
nuclear factor kappaB in, in HIV transmission enhancement, 1343
squamous intraepithelial lesions, human papillomavirus in, 252
Chancroid
epidemiology
in genital ulcer disease, 1795
Mississippi, 1060
human experimental model for, 1684
pathogenesis, *Haemophilus ducreyi* isogenic hemolysin-deficient mutant in, 191
Chemokine(s)
in cervical secretions, in HIV infection, 1334
from neutrophils
in *Escherichia coli* lipopolysaccharide response, 127
in *Mycobacterium tuberculosis* response, 127
in tuberculous pleurisy, 1450
Chemokine receptors (*See also* CC5)
in HIV infection pathogenesis, 1623
Chemotherapy, hepatosplenic candidiasis in, interleukin-10 in, 589
Chickenpox (*See* Varicella-zoster virus)
Children (*See* Pediatric patients)
*Chlamydia*, infections
asymptomatic, epidemiology, in military population, 1202
HIV infection, transmission risk in, 1174
*Chlamydia pneumoniae*, in mononuclear cells, in cardiovascular disease, 274
*Chlamydia trachomatis*
immune response to, serovar-specific, 1713
infection
with *Neisseria gonorrhoeae* infection, immune response in, 742

transmission, 1707
salpingitis, in HIV infection, 1352
*A Christmas Carol*, Tiny Tim character, diagnosis, 596
Chromatography, anion-exchange, in HIV protein separation, 1635
Chromosome length polymorphism, *Cryptococcus neoformans*, mouse model, 1761
Chronic obstructive pulmonary disease, *Haemophilus influenzae* infections in, adherence factors in, 1067
Cidofovir, for cytomegalovirus infections, antiviral susceptibility, 1821
Ciprofloxacin
for *Escherichia coli* diarrhea, enteroaggregative, in HIV infection, 1369
for *Pseudomonas aeruginosa* sepsis, rat model, 1205
Clarithromycin, for *Mycobacterium avium* complex infections
with HIV infection, 1446
mouse model, 896
*Coccidioides immitis*, meningitis, rabbit model, 1217
Colonization
*Candida*, in interferon-$\gamma$ deficiency, mouse model, 478
*Escherichia coli*, vaginal, vs. hydrogen peroxide-producing lactobacilli, urinary tract infection and, 446
*Neisseria meningitidis*, in military recruits, 451
pneumococci, oropharyngeal, anticapsular polysaccharide antibodies and, rat model, 878
*Yersinia pestis*, in flea, 1406
Colony-forming units, in HIV infection, highly active retroviral therapy effects on, 1299
Complement
activation, antibody-independent, cytomegalovirus-infected fibroblasts in, 1597
opsonization by, *Helicobacter pylori* urease effects on, 1521
Condylomata acuminata, treatment, 551
Congenital infections (*See also* Human immunodeficiency virus infection, transmission, perinatal)
human herpesvirus 6, 544
rubella, epidemiology, United States, 636
varicella-zoster virus, Barrett's esophagus in, 539
Contraception, hormonal, HIV, transmission risk and, 1053
Convulsions, in *Plasmodium berghei* cerebral malaria, treatment, mouse model, 1225
Coronary artery disease
*Chlamydia pneumoniae* in, 274
cytomegalovirus in, 1860
*Coxiella burnetii*, endocarditis, guinea pig model, 278
*Cryptococcus neoformans*
in CD4 expression on monocytes, 1464
glucuronoxylomannan, transendothelial leukocyte migration and, 1231
infections
in HIV infection, 114
treatment, monoclonal antibodies, mouse model, 1213
in interleukin-15 release, 803
virulence factors
in HIV infection, mouse model, 1761
monoclonal antibodies to, mouse model, 12
*Cryptosporidium*
antigens, antibody response to, 827
infections
in HIV infection, 114
combination therapy for, 900, 915
genotypic analysis in, 834
Israeli Bedouin infants, 1081
CTLA-4 (CD152 molecule), blockade, in *Leishmania chagasi* infections, mouse model, 1847
CXCR-4 chemokine receptor, in HIV infection pathogenesis, 1623
Cysteine protease-related antigens, *Plasmodium falciparum*, humoral immune response to, 285
Cysteine proteases, *Trichomonas vaginalis*, in secretory leukocyte protease inhibitor degradation, 815
Cytochrome b gene, *Pneumocystis carinii*, sequence polymorphisms, prophylaxis failure and, 1767
Cytokines (*See also specific cytokines*)
in aspergillosis immune response, mouse model, 1750
genes, amphotericin B activation of, 1726
granulocyte colony-stimulating factor effects on, 891
in HIV infection, before CD4 T cell inflection point, 423
inhibition, lipopolysaccharide-induced, in systemic inflammatory response syndrome, 883
in *Neisseria gonorrhoeae* infections, in concomitant infections, 742
in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 1421
in varicella-zoster virus cultures, S95
in varicella-zoster virus immune response, 940
Cytolysin, *Gardnerella vaginalis*, immune response to, 1698
Cytomegalovirus
antibody response to, kinetics, in bone marrow transplantation, 1233
antigen pp65, in bone marrow transplantation, 1153
in fibroblasts, in classical complement pathway activation, antibody-independent, 1597
infections
in bone marrow transplantation, prophylaxis, 1153
diagnosis, IgG avidity index in, 599
in HIV infection, retinitis, 114
in kidney transplantation, human herpesvirus 6 reactivation in, 1783
monitoring, in bone marrow transplantation, in pediatric patients, 1244
prediction, in kidney transplantaon in, 1145
monitoring, in kidney transplantation, 1544
polymerase chain reaction detection, 921, 1544
resistance in
foscarnet, 526
ganciclovir, 531, 535
retinitis
antiviral susceptibilities, 1821
in HIV, 114, 1149
Cytotoxins, *Helicobacter pylori*, 207, 220

ddC (dideoxycytosine), for HIV infection, in combination therapy, 340
Death (*See* Mortality)
Defensins, in *Haemophilus influenzae* adherence, to lung epithelial cells, 1067
Dementia, HIV–associated, treatment, antiretroviral agents, 1000
Demyelination, in peripheral nerves, in Lyme disease, rhesus monkey model, 722
Dendritic cells, in varicella-zoster virus peptide immune response assay, S39
Dengue virus, infections, pathogenesis, vs. yellow fever virus, 1270
Depression, varicella-zoster virus cellular immunity in, S104
Dialysis, bloodstream infections in, outbreak, 783
Diarrhea
astrovirus, epidemiology, Mayan Mexicans, 334
*Cryptosporidium parvum*, in HIV infection
combination therapy for, 900, 915
genotypic analysis, 834
*Escherichia coli*, enteroaggregative, in HIV infection, 185
treatment, 1369
etiology, Israeli Bedouin infants, 1081
*Helicobacter pylori*, vacuolating toxin in, 1373

rotavirus, natural protection after, 1562
torovirus, in pediatric patients, 1263
Dideoxycytosine, for HIV infection, in combination therapy, 340
Dihydrofolate reductase, mutations, *Streptococcus pneumoniae* resistance in, 700
Disco fever (meningococcal disease), in Argentina, 266
DNA analysis
for sexually transmitted diseases, in military population, 1202
for *Staphylococcus aureus*, methicillin-resistant, 164
DNA polymerase, mutations, in cytomegalovirus foscarnet resistance, 526
DNA-based vaccines, HIV, clinical trials, 92
Dorsal root ganglia, varicella-zoster virus in, rat model, S48
Drug abuse, HIV infection in
with dual-tropic viral variants, progression, 388
opportunistic infections in, 114
Drug resistance
acyclovir, herpes simplex virus, 297
attributable mortality and, 917
*Bacillus popilliae*, vancomycin, 584
cytomegalovirus
foscarnet, 526
ganciclovir, 531, 535
*Enterococcus faecium*, $\beta$-lactams, 159
foscarnet
cytomegalovirus, 526
varicella-zoster virus, S55
ganciclovir, cytomegalovirus, 531, 535
herpes simplex virus, acyclovir, 297, 618
HIV, 1497
indinavir, 360
indinavir, HIV, 360
influenza virus, zanamivir, 1257
isoniazid, *Mycobacterium tuberculosis*, 769
methicillin, *Staphylococcus aureus*, 577
*Mycobacterium tuberculosis*, isoniazid, 769
*Staphylococcus aureus*, methicillin, 164, 577
*Streptococcus pneumoniae*, trimethoprim, 700
trimethoprim, *Streptococcus pneumoniae*, 700
vancomycin, *Bacillus popilliae*, 584
varicella-zoster virus, foscarnet, S55
zanamivir, influenza virus, 1257

Ebola hemorrhagic fever, prophylaxis, mouse model, 651
Editorials
cryptosporidiosis in HIV infection, 915
Infectious Diseases Society of America publications, August 1998, page E1
*Ehrlichia*, immunodiagnostic assays for, 1835
Elderly persons
herpes zoster in, risk factors for, S67
pneumococcal vaccine response in, 431
varicella-zoster virus vaccination in, S99, S109
Electrophoresis
for *Kingella kingae*, 1848
for methicillin-resistant *Staphylococcus aureus* strains, 577
for *Neisseria meningitidis* typing, 266
ELISA (*See* Enzyme-linked immunosorbent assay)
Encephalitis, herpes simplex virus, granulocyte-macrophage colony-stimulating factor production in, rat model, 16
*Encephalitozoon intestinalis*
infections, in HIV infection, risk factors for, 904
in nonhumans, 820
Encephalopathy, spongiform
strain variations, molecular analysis, 693
transmission, 949
Endarteritis obliterans, *Coccidioides immitis*, rabbit model, 1217
Endocarditis, *Coxiella burnetii*, guinea pig model, 278
Endocytosis, varicella-zoster virus, S2
Endothelial cells, brain, activation in *Listeria monocytogenes* infections, 1658
Endotoxemia
in bacteremia, gram-negative, 270
leptin levels in, 887
Endotoxin (*See* Lipopolysaccharide)
Enoyl reductase, *Mycobacterium tuberculosis*, mutations, isoniazid resistance and, 769
*Enterobacter cloacae*, bacteremia, in hemodialysis, 783
*Enterococcus faecalis*
bacteremia, in hemodialysis, 783
mutants, peritonitis, mouse model, 1416
*Enterococcus faecium*, resistance in, $\beta$-lactam, penicillin-binding protein 5 sequences in, 159
*Enterocytozoon bieneusi*, infections, in HIV infection, risk factors for, 904
Enterotoxicity, *Helicobacter pylori* vacuolating cytotoxin, 1373
Enteroviruses, infections
after measles-mumps-rubella vaccination, simulating vaccine failure, 1567
testing for, in dilated cardiomyopathy, 256
*env* gene, HIV
in DNA-based vaccines, 92
subtype E, diversification, 1507
Environmental factors, diarrhea, in Israeli Bedouin infants, 1081
Enzyme-linked immunosorbent assay
for cytomegalovirus, in bone marrow transplantation, 1233
for *Helicobacter pylori*, in pediatric patients, 460
for human herpesvirus 8, interassay correlation, 304
for HIV, 1306
for *Mycobacterium tuberculosis* antigen 85 complex, 1115
Enzyme-linked immunospot assay, for CD8 T cells, in HIV infection, 260
Epidemiology
adenovirus antibodies, serotypes 4 and 7, military population, 1776
astrovirus infections, Mayan Mexicans, 334
bloodstream infections, in hemodialysis, 783
botulism, Texas, 172
congenital rubella syndrome, United States, 636
*Encephalitozoon intestinalis* infections, animals, 820
genital ulcers
atypical, Mississippi, 1060
in HIV infection, 1795
Guillain-Barré syndrome, 1228
*Helicobacter pylori*
Japan, 717
Mexico, 1089
vacuolating cytotoxins, China, 220
hepatitis A, United States, 1579
hepatitis B, United States (1976–1994), 954
hepatitis G
with HIV infection, mothers and children, 862
Scottish blood donors, 1779
herpes zoster, S91
HIV infection, with genital ulcer disease, Mississippi, 1060
human herpesvirus 8 and antibodies
Brazil and Colorado, 1488
Honduras, 547
Zambia, 1787
influenza, mortality, pandemic vs. epidemic, 53

leptospirosis, with pulmonary hemorrhage, Nicaragua, 1457
measles virus antibody, in HIV infection, Northern California, 1177
neurosyphilis, in HIV infection, New Orleans (1990-1997), 1229
Norwalk-like virus gastroenteritis, United States, 1571
rubella, molecular analysis, North America, Europe, Asia, 642
sexually transmitted diseases, asymptomatic, military populations, 1202
*Staphylococcus aureus*, methicillin-resistant, New York hospitals, 164
syphilis, in HIV infection, New Orleans (1990-1997), 1229
*Vibrio vulnificus* infections, vs. oyster harvesting season, 752
Epithelial cells
lung, *Haemophilus influenzae* adherence to, defensins in, 1067
renal tubular, apoptosis, *Escherichia coli* Shiga toxin in, 178
streptococci group A (*Streptococcus pyogenes*) entry into, 147
Errata
*Chlamydia*-like bacterium (1998;177:1425-1429), 1553
cytomegalovirus-induced chorioretinal disease (1998;177:1778), 1553
nonencapsulated *Haemophilus influenzae* (1996;173:180-186), 296
*Pneumocystis carinii* antigens (1998;178:235-242), 924
Erythema migrans, in Lyme disease
*Borrelia burgdorferi* gene expression during, vs. arthritis, 1198
*Borrelia burgdorferi* outer surface protein antibody response in, 1676
*Escherichia coli*
bacteremia, treatment, endotoxemia in, 270
colonization, vaginal, vs. hydrogen peroxide-producing lactobacilli, urinary tract infection and, 446
diarrhea
enteroaggregative, in HIV infection, 185
Israeli Bedouin infants, 1081
endotoxin, neutrophil response to, 127
infections, enteroaggregative, in HIV infection, 185
treatment, 1369
lipopolysaccharides, O157 vs. O55, 920, 1551
Shiga toxins, in renal tubular epithelial cell apoptosis, 178
Esophagus, Barrett's, in congenital varicella-zoster virus infection, 539
Estradiol levels, vs. HIV shedding, 983
Ethambutol, for *Mycobacterium avium* complex infections, 121
with HIV infection, 1446
Exotoxins, staphylococcal, in interleukin-8 production, 573
Eye
retinal necrosis in, viral, pathogenesis, T cells in, 27
retinitis (*See* Retinitis)
varicella-zoster virus uveitis, guinea pig model, 310

Fallopian tubes, infections, in HIV infection, 1352
Famciclovir
for hepatitis B, 1483
for herpes zoster, cost effectiveness, S85
for postherpetic neuralgia, S76
Fas and Fas ligand, in HIV infection, 1030
Fc receptor, varicella-zoster virus, S2
Feline immunodeficiency virus
infections
CD8 T cell characteristics in, 968
toxoplasmosis in, interleukin ratios in, 503
maternal-fetal transmission, 960
tissue tropism, 960
Fibroblasts, cytomegalovirus-infected, in classical complement pathway activation, antibody-independent, 1597
Fibronectin, organism binding to, hemoglobin effects on, 497
Filgrastim (*See* Granulocyte colony-stimulating factor)
Fleas, in plague transmission, *Yersinia pestis* plasminogen activator and, 1406
Fluorescent treponemal tests, false-negative, 294
Foodborne diseases
botulism, Texas, 172
Norwalk-like virus gastroenteritis, 1571
*Vibrio vulnificus* infections, vs. oyster harvesting season, 752
Foscarnet
for cytomegalovirus infections, antiviral susceptibility, 1821
resistance to
cytomegalovirus, 526
varicella-zoster virus, S55
Fulminant hepatitis, etiology, in Japan, 325
Fungemia, in hemodialysis, outbreak, 783

G protein, respiratory syncytial virus, variations, 925
*gag* gene and product, HIV, cytotoxic T cell response to, 1008
Ganciclovir, for cytomegalovirus infections
antiviral susceptibility, 1821
prophylactic, in bone marrow transplantation, 1153
resistance to, 535
response to, polymerase chain reaction for, 626
*Gardnerella vaginalis*, cytolysin, immune response to, 1698
Gastric acid, *Helicobacter pylori* tolerance, 213
Gastric cells, *Helicobacter pylori* binding to, Lewis antigen–independent, 1379
Gastritis, *Helicobacter pylori* in (*See Helicobacter pylori*)
Gastroenteritis (*See also* Diarrhea)
astrovirus, epidemiology, Mayan Mexicans, 334
Norwalk-like viruses, epidemiology, United States, 1571
rotavirus, treatment, prostaglandin A in, 564
torovirus, in pediatric patients, 1263
*Vibrio vulnificus*, epidemiology, vs. oyster harvesting season, 752
GB virus C (hepatitis G virus)
conserved ambisense sequences in, 1185
infections
in HIV infection, 862
in Scottish blood donors, 1779
Gene transfer therapy, interferon-γ, for visceral leishmaniasis, mouse model, 908
Genital tract infections
gonorrhea (*See Neisseria gonorrhoeae*)
herpes simplex virus (*See also* Herpes simplex virus, type 2)
diagnosis, molecular methods for, 243
recurrent, suppression with valaciclovir, 603
vaccination, cervical antibody responses to, 1
HIV, transmission risk and, 1053, 1174
HIV
β-chemokine secretion in, 1334
viral shedding in, vs. menstrual cycle, 983
human papillomavirus
rare types, 252
treatment, 551
in women who have sex with women, 1604
salpingitis, in HIV infection, 1352
Giardiasis, Israeli Bedouin infants, 1081
Glucuronoxylomannan, *Cryptococcus neoformans*
monoclonal antibodies to, in cryptococcosis, mouse model, 1213
transendothelial leukocyte migration and, 1231
Glycolipids, *Candida albicans*, shedding, in macrophage interactions, 792
Glycoprotein(s)
herpes simplex virus type 1, in vaccine preparation, mouse model, 611
herpes simplex virus type 2

characteristics, 8
in vaccine preparation, cervical antibody responses to, 1
varicella-zoster virus
analysis, S22
characteristics, S2, S13
immune response to, guinea pig model, 310
intracellular transport, S7
purification, S13
recombinant, in baculovirus system, S13
Glycoprotein B, cytomegalovirus, subtyping, in retinitis, in HIV infection, 1149
Glycoprotein E, varicella-zoster virus, analysis, S22
Glycoprotein I, varicella-zoster virus
analysis, S22
open-reading frame 29 binding to, S34
Glycotyping, prion proteins, 693
Golgi network, varicella-zoster virus in, S7
Gonorrhea (*See Neisseria gonorrhoeae*, infections)
gp120 protein, HIV
antibodies to, in vaccination, 92
displacement by saliva, 1635
humoral immune response to, vs. progression, 1306
gp160 protein, HIV
antibodies to, in vaccination, 92
humoral immune response to, vs. progression, 1306
Gram-negative organisms, bacteremia, treatment, endotoxemia in, 270
Granulocyte colony-stimulating factor
for HIV infection, 686
neutrophil enhancement from, for *Mycobacterium avium* complex inhibition, 1530
for inflammation, alcohol ingestion and, 891
for pneumonia, 1075
for polymicrobial peritonitis and sepsis, with antibiotics, mouse model, 471
Granulocyte-macrophage colony-stimulating factor
in sepsis, monocyte anergy and, 1421
in T cell response to herpes simplex virus type 1, rat model, 16
Guillain-Barré syndrome
in *Campylobacter jejuni* infections, 1549
epidemiology, 1228

HAART (highly active retroviral therapy), for HIV infection
cytotoxic T cell response in, 61
with dementia, 1000
immunologic response to, clinical trials, 70
with *Mycobacterium avium* complex infection, 1446
progenitor cell function in, 1299
T cell antigens and, 1279
*Haemophilus ducreyi*
epidemiology
in genital ulcers, 1795
Mississippi, 1060
immune response to, 1688
infections, human experimental model for, 1684
isogenic hemolysin-deficient mutant, 191
*Haemophilus influenzae*
adherence, to lung epithelial cells, defensins in, 1067
bacteremia, treatment, endotoxemia in, 270
Heart
defects of, in congenital rubella syndrome, epidemiology, 636
dilated cardiomyopathy, enterovirus infection testing in, 256
surgery on, *Nocardia farcinica* infections after, 1539
Heat shock proteins, *Mycobacterium avium* complex, genetic diversity, 776
*Helicobacter pylori*
acid tolerance, 213
binding properties, Lewis antigen-independent, 1379
*cagA*$^+$ strains vs. *cagA*$^-$ strains, 213
epidemiology
Japan, 717
Mexico, 1089
serologic testing
Pediatric patients, 460
in pediatric patients, 460
urease
in mucosal macrophage activation, 1516
opsonization effects, 1521
*vacA* gene, sequence analysis, in cytotoxic and noncytotoxic strains, 1391
vaccination, pig model, 1399
vacuolating cytotoxins, 207, 220
enterotoxic effect, in vitro studies, 1373
gene sequence analysis, 1391
virulence factors, 207, 220, 1373, 1391
Hemagglutinin, filamentous, *Bordetella pertussis*, cellular immune response to, 466
Hematopoietic stem cells, HIV infection, chemokine receptors in, 1623
Hemodialysis, bloodstream infections in, outbreak, 783
Hemoglobin, in fibronectin-organism binding, 497
Hemolysins, *Haemophilus ducreyi*, 191
Hemophilia, hepatitis C in, antibody kinetics in, 556
Hemorrhage, pulmonary, in leptospirosis, epidemiology, Nicaragua, 1457
Hemorrhagic fever
Ebola, prophylaxis, mouse model, 651
viral, virus inactivation, in malaria testing, 1852
Hepatitis, fulminant, etiology, in Japan, 325
Hepatitis A virus
infections, epidemiology, United States, 1579
vaccination
dose response study, 1181
epidemiology patterns and, 1579
Hepatitis B virus
clearance after bone marrow transplantation, 1585
infections
combination therapy for, 1483
epidemiology, United States (1976–1994), 954
fulminant, etiology, in Japan, 325
thymosin $\alpha$[cf15]1 for, S gene mutant emergence in, 866
vaccination, 954
Hepatitis C virus
clearance, major histocompatibility complex class II alleles and, 39
genetic analysis, 1193
infections
chimpanzee model, 1193
fulminant, etiology, in Japan, 325
in hemophilia, antibody kinetics in, 556
in HIV infection, in neonates, 1047
interleukin-12 in, vs. hepatocellular damage, 247
replication in lymphoid tissue, in HIV infection, 1189
transmission, in HIV-infected infants, 1047
Hepatitis D virus, infections, fulminant, etiology, in Japan, 325
Hepatitis E virus, infections, fulminant, etiology, in Japan, 325
Hepatitis G virus (GB virus C)
conserved ambisense sequences in, 1185
infections
in HIV infection, 862
in Scottish blood donors, 1779
Hepatocytes, apoptosis, in dengue fever, 1270
Herpes simplex virus
encephalitis, granulocyte-macrophage colony-stimulating factor

production in, rat model, 16
genital infections (*See also* Herpes simplex virus, type 2)
epidemiology, 1795
suppression with valaciclovir, 603
infections, in HIV infection, 114
prevention with acyclovir, 349
resistance in, acyclovir, 297
retinal necrosis, pathogenesis, T cells in, 27
shedding, in homosexual population, 978
type 1
recurrent, in bone marrow transplantation, 618
resistance in, acyclovir, 618
T cell response to, granulocyte-macrophage colony-stimulating factor production, rat model, 16
vaccination, antibody response to, mouse model, 611
type 2
cell culture of, 8
diagnosis, molecular methods for, 243
glycoprotein gene sequences in, 8
infections
HIV infection transmission risk in, 1174
reactivation frequency in HIV infection, 1616
vaccination, glycoprotein subunit, cervical antibody responses to, 1
Herpes zoster
clinical features, S91
in depression, S104
epidemiology, S91
pain during/after
factors affecting, S76
prevention, S91
risk factors for, S71
treatment timing and, S81
pathology, S91
risk factors for, in elderly persons, S67
treatment
cost effectiveness, S85
early vs. late, S81
vaccination and, S91
after varicella-zoster vaccination, S109
Herpesviruses (*See specific viruses, e.g.*, Human herpesvirus 8)
Histoplasmosis, in HIV infection, 114
HIV infection (*See* Human immunodeficiency virus infection)
Hong Kong influenza (1968–1969), epidemiology, mortality in, 53
Hormones, female
HIV infection transmission risk and, 1053
vs. HIV shedding, 983
Host defense, *Aspergillus fumigatus*, mouse model, 1472
Human granulocytic ehrlichiosis, immunodiagnostic assays for, 1835
Human herpesvirus 6
congenital, 544
infections
with cytomegalovirus infections, in kidney transplantation, 1783
after measles-mumps-rubella vaccination, simulating vaccine failure, 1567
in pediatric patients, diagnosis, 1250
Human herpesvirus 7, persistence in normal tissues, 841
Human herpesvirus 8 (*See also* Kaposi's sarcoma)
antibodies to
epidemiology
Brazil and Colorado, 1488
Zambia, 1787
in multiple myeloma, 846
DNA, detection in tissues and bodily fluids, 1610
epidemiology, Honduras, 547
infections, reactivation, in kidney transplantation, 1791
serologic tests, interassay correlation, 304
variants, in France, 1546
Human immunodeficiency virus
antigens, CD8 T cells responsive to, quantification, 260
in cervical secretions, β-chemokine secretion and, 1334
diversity, vaccines and, 1040
dual-tropic variants, in drug users, 388
dynamics, in primary infection, 1812
envelope peptides and proteins, vs. disease progression, 1306
in hematopoietic stem cells, chemokine receptors and, 1623
inhibition by saliva, 1635
replication, T cell activation and cell cycle antigens and, 1279
resistance in
combination therapy, 1497
indinavir, 360
RNA
in cervical secretions, β-chemokine secretion and, 1334
nucleoside reverse transcriptase inhibitors effects on, 1803
shedding, in menstrual cycle, 983
subtype E, *env* gene diversity in, 1507
syncytium-inducing variant
conversion from non–syncytium-inducing variant, 1806
in drug users, 388
in homosexual population, 397
Human immunodeficiency virus infection
anergy in, vs. CD4 T cell function, 1024
animal models (*See* Feline immunodeficiency virus)
antibodies to, in vaccination, 92
aspergillosis in, viral load in, 1642
asymptomatic, imiquimod for, 858
bacteremia in, viral load in, 1642
*Candida albicans* infections in, cellular immune response in, 488
candidiasis in, 114
cellulitis in, viral load in, 1642
β-chemokine secretion in, in genital tract virus shedding, 1334
cryptococcosis in, 114
virulence, mouse model, 1761
cryptosporidiosis in, 114
combination therapy for, 900, 915
genotypic analysis, 834
cytomegalovirus infections in
foscarnet resistance in, 526
retinitis, 114, 1149
diagnosis, serology in, 560
diarrhea in, *Escherichia coli*, enteroaggregative, 185
treatment, 1369
double-positive CD4CD8 T cell population in, cytotoxic function, 1158
epidemiology, in genital ulcer disease, Mississippi, 1060
*Escherichia coli* infections in, enteroaggregative, 185
treatment, 1369
Fas and Fas ligand in, 1030
genital ulcers in, 243, 1795
granulocyte colony-stimulating factor in, neutrophil enhancement from, in *Mycobacterium avium* complex inhibition, 1530
hepatitis C in, in neonates, 1047
hepatitis C virus replication in lymphoid tissue, 1189
hepatitis G in, 862
herpes simplex virus infections in, 114
prevention with acyclovir, 349
type 2, reactivation frequency, 1616
histoplasmosis in, 114

in homosexual population, opportunistic infections in, 114
human papillomavirus infections in
in homosexual population, 45
novel sequence in, 1492
humoral immune response to, vs. progression, 1306
Kaposi's sarcoma in, 114
human herpesvirus 8 antibody tests in, 304
lymphocyte-reactive autoantibodies in, 404
matrix metalloproteinase-9 in, in cerebrospinal fluid, 854
measles antibody in, 1177
microsporidiosis in, risk factors for, 904
mortality in, in pediatric patients
predictors, 680
in Zimbabwe, 109
*Mycobacterium avium* complex infections in, 114
interleukin-12 production in, 1209
strains, in pediatric patients, 776
treatment, 1446
neurosyphilis in, epidemiology, New Orleans (1990–1997), 1229
nonprogression
cytotoxic T cells in, 1008
lymphocyte apoptosis rate in, 669
non–syncytium-inducing HIV variant in, 1806
opportunistic infections in, in homosexual population, 114
pathogenesis, hematopoietic stem cell entry, 1623
in pediatric patients (*See* Pediatric patients, human immunodeficiency virus infection in)
*Pneumocystis carinii* pneumonia in, 114
risk factors for, 1126
viral load in, 1642
in pregnancy (*See* Pregnancy, HIV in)
prevention, in neonates, 1327
primary (acute)
prognosis, 375
treatment, 80
viral dynamics in, 1812
prognosis
in pediatric patients, 375
T cell subsets in, 1166
progression
CCR5 mutation and, 1019, 1163
cytokine levels and, 423
cytotoxic T cells in, 1008
with dual-tropic viral variants, in drug users, 388
vs. humoral immune response, 1306
lymphocyte apoptosis rate and, 669
major histocompatibility complex genotype and, 1799
in *Mycobacterium avium* complex infections, 1209
in pediatric patients, 375
with syncytium-inducing variant, 397, 1806
T cell inflection point in, 423
vs. viral load, in pediatric patients, 101
progressive multifocal leukoencephalopathy in, 1816
salpingitis in, 1352
sexually transmitted disease transmission in, 1174
sinusitis in, viral load in, 1642
slow progressors, humoral immune response in, 1306
*Streptococcus pneumoniae* vaccination in, antibody response, molecular structure, 707
susceptibility to, in trichomoniasis, 815
syphilis in, epidemiology, New Orleans (1990–1997), 1229
T cells in
in antiretroviral triple therapy, 61, 70
apoptosis
Fas and Fas ligand in, 1030
in nonprogressors, 669
retinoic acid inhibition, 1288
in *Candida albicans* antigen recognition, 488
vs. CCR5 mutations, 1019
CD8, cat model, 968
CD34, highly active retroviral therapy effects on, 1299
CD4CD8 double-positive, cytotoxic function, 1158
cross-clade response, 1040
cytotoxic
gag-specific response in, 1008
in pediatric patients, 1317
depletion, lymphocyte-reactive autoantibodies in, 404
with dual-tropic variants, in drug users, 388
Fas and Fas ligand in, 1030
granulocyte colony-stimulating factor effects on, 686
vs. hypersensitivity skin test anergy, 1024
inflection point, vs. viral load, 423
measurement, 260
*Pneumocystis carinii* pneumonia risk in, 1126
proliferation antigens, viral load and, 1279
syncytium-inducing variant, 1806
in homosexual population, 397
vs. time, 1166
in zidovudine therapy, for primary infection, 80
toxoplasmosis in, 114
interleukin ratios in, cat model, 503
viral load in, 1642
transmission
hormonal contraception and, 1053
kappaB enhancement, 1343
vs. menstrual cycle status, 983
monocyte CD4 levels and, 1464
perinatal
cat model, 960
CCR5 mutation and, 1019
cytotoxic T cell responses and, 1317
diagnosis, 560
prognostic indicators, 375
time vs. mortality rate, 680
viral load vs. progression, 101
in Zimbabwe, 109
protection against, in CCR5 mutation, 1163
sexually transmitted diseases and, 1053, 1174
treatment
acyclovir, 349
antiretroviral agents (*See also* HAART (highly active retroviral therapy); *specific agents*)
response to, 662
viral RNA level monitoring in, 1803
combination, trial designs for, 340
cytotoxic T cell response in, in antiretroviral triple therapy, 61
in dementia, 1000
drug resistance in, 1497
granulocyte colony-stimulating factor, 686
highly active retroviral therapy (*See* HAART (highly active retroviral therapy))
immune globulin, 597
interleukin-2, 992
nevirapine, 368
primary, 80
protease inhibitor potency in monocytes/macrophages, 413
salvage, trial designs for, 340
zidovudine with interleukin-2, 1170

tuberculosis in, 114
pentoxifylline safety in, 1861
vaccination
clinical trials, 92
diverse clades and, 1040
mouse model, 1359
neutralizing activity in, 1502
rabbit model, 850
varicella-zoster virus infections in, S55
prevention with acyclovir, 349
viral load in
acute illness effects on, 1642
vs. CCR5 mutations, 1019
in dual nucleoside regimens, 662
major histocompatibility complex genotype and, 1799
in primary infection, 1812
prognosis prediction and, in pediatric patients, 375
vs. progression, in pediatric patients, 101
T cell activation and cell cycle antigens and, 1279
Human leukocyte antigens
abnormal, in septic shock, 1421
activation marker, HIV load and, 1279
disparate, HIV vaccination reactions and, 1040
genotypes, in HIV infection progression, 1799
in hepatitis C virus clearance and, 39
Human papillomavirus
A15, discovery, 1492
infections
in HIV infection
in homosexual men, 45
novel sequence in, 1492
treatment, 551
in women who have sex with women, 1604
rare types, in genital lesions, 252
Human T lymphotropic virus type I, infections, with strongyloidiasis, cytokine response in, 1856
Humoral immune response (*See also* Antibody(ies))
to cytomegalovirus, kinetics, in bone marrow transplantation, 1233
to HIV, vs. progression, 1306
to *Plasmodium falciparum* cysteine protease-related antigens, 285
to *Schistosoma haemobium*, chemotherapy effects on, 289
to tetanus vaccination in onchocerciasis, 1133
to varicella-zoster virus, IE 63 protein in, S43
Hydrogen peroxide, lactobacilli producing, vaginal
vs. *Escherichia coli* colonization, urinary tract infections and, 446
nonoxynol-9 effects on, 441
Hyper-IgM syndrome, X-linked, parvovirus B19–induced anemia in, 318
Hypersensitivity, delayed-type, in *Haemophilus ducreyi* infection, 1688
Hypersensitivity skin test, in HIV infection, vs. CD4 T cell function, 1024

Ibuprofen, leptin levels and, 887
IE62 protein, varicella-zoster virus, nuclear localization, S16
IE63 protein, varicella-zoster virus, immune response to, S43
Imiquimod
for condylomata acuminata, 551
for HIV infection, asymptomatic, 858
Immune globulin
cytomegalovirus, in kidney transplantation, 1783
in HIV infection, 597
intravenous, in parvovirus B19 infections, in X-linked hyper-IgM syndrome, 318
Immune response (*See also* Cellular immune response; Humoral immune response)
to bacterial vaginosis, 1698
to *Haemophilus ducreyi*, 1688
to HIV infection, gag-specific, 1008
to influenza vaccination, 933
to malaria vaccination, 1139
to *Neisseria meningitidis*, in military recruits, 451
to rotavirus infections, natural protection from, 1562
to *Schistosoma haematobium* adult worm antigen, 512
to varicella-zoster virus peptides, dendritic cell assay for, S39
Immunoblot assays
for *Cryptosporidium* antibodies, 827
for hepatitis C virus antibodies, in hemophilia, 556
for *Kingella kingae*, 1848
for molluscum contagiosum virus immunoreactive proteins, 1230
for parvovirus B19, 1826
for prion proteins, 693
Immunodeficiency (*See also* Human immunodeficiency virus infection; Transplantation)
candidiasis susceptibility in, mouse model, 478
herpes simplex virus characterization in, acyclovir-resistant, 297
influenza B virus infection in, zanamivir resistance in, 1257
in *Mycobacterium avium* complex infections, tree kangaroo model, 1719
primary combined, cytomegalovirus infections in, ganciclovir resistance in, 535
*Pseudomonas aeruginosa* sepsis in, interleukin-11 in, rat model, 1205
in X-linked hyper-IgM syndrome, parvovirus B19–induced anemia in, 318
Immunodiagnostic assays, for *Ehrlichia*, 1835
Immunofluorescence assays, for human herpesvirus 8
indirect, 1791
interassay correlation, 304
Immunoglobulin(s) (*See also* Immune globulin)
in herpes simplex virus type 2 glycoprotein subunit vaccination, 1
Immunoglobulin A
degradation, in bacterial vaginosis, 1698
rotavirus, protective effects, 1562
Immunoglobulin E, in *Schistosoma haematobium* infections, 512
Immunoglobulin G
*Borrelia burgdorferi*, outer surface protein C, mouse model, 733
in parvovirus B19, 1826
Immunoglobulin G avidity index, in cytomegalovirus infections, 599
Immunoglobulin M
*Borrelia burgdorferi*, outer surface protein C, mouse model, 733
degradation, in bacterial vaginosis, 1698
monoclonal, in cryptococcosis, mouse model, 1213
Immunohistochemistry, human herpesvirus 7 detection, 841
Immunomodulating therapy, for abdominal sepsis, rat model, 200
Indinavir, resistance to, 1497
human immuatal sepsis inhibition, 875
Infants (*See* Neonatal infections; Pediatric patients)
Infection control
in hemodialysis, 783
in surgery, 1539
Inflammation
*Aspergillus fumigatus*, mouse model, 1472
granulocyte colony-stimulating factor in, alcohol use and, 891
Inflection point, CD4 T cell depletion, in HIV infection, vs. viral load, 423
Influenza virus
A/HongKong/156/97, characterization, mouse model, 1592
chimeric, as vector, in HIV vaccine preparation, mouse model, 1359
infections
epidemiology, mortality, pandemic vs. epidemic, 53

treatment, zanamivir, mouse model, 1592
resistance in, zanamivir, 1257
vaccination, immune response in, 933
Intercellular adhesion molecules, in *Listeria monocytogenes* infections, 1658
Interferon(s), induction, imiquimod in, 858
Interferon-$\alpha$, for hepatitis B, 1483
Interferon-$\gamma$
in alveolar lymphocytes, in tuberculosis, 1434
in bacille Calmette-Guérin vaccination, 138
in candidiasis susceptibility, mouse model, 478
in gene transfer therapy, for visceral leishmaniasis, mouse model, 908
in HIV infection, from CD4CD8 double-positive T cells, 1158
in human T lymphotropic virus type I infection with strongyloidiasis, 1856
in interleukin-18 enhancement, 1830
in interleukin-12 regulation, in *Mycobacterium tuberculosis* monocyte infections, 1105
in neonatal sepsis inhibition, 875
regulation, in interferon-$\gamma$ receptor deficiency, in mycobacterial infections, 1095
in retinal necrosis pathogenesis, viral, 27
in varicella-zoster virus cultures, S95
in varicella-zoster virus immune response, 940
Interferon-$\gamma$-inducing factor (interleukin-18), in interferon-$\tau$ production, lipopolysaccharide-induced, 1830
Interferon-$\gamma$ receptor deficiency, abnormal cytokine regulation in, in mycobacterial infections, 1095
Interleukin(s)
in acute infections, in HIV infection, 1642
in *Aspergillus fumigatus* infections, mouse model, 1472
in *Helicobacter pylori* urease induction, 1516
in *Neisseria gonorrhoeae* infections, in concomitant infections, 742
ratios, in feline immunodeficiency virus infection, 503
in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 1421
in varicella-zoster virus cultures, S95
Interleukin-1$\beta$
genes, amphotericin B activation of, 1726
in *Plasmodium falciparum* malaria, 520
Interleukin-1 receptor, genes, amphotericin B activation of, 1726
Interleukin-1 receptor antagonist, granulocyte colony-stimulating factor effects on, 891
Interleukin-2
granulocyte colony-stimulating factor effects on, in HIV infection, 686
for HIV infection
administration methods, 992
with zidovudine, 1170
Interleukin-2 receptor, soluble, in HIV infection, before CD4 T cell inflection point, 423
Interleukin-4
in human T lymphotropic virus type I infection with strongyloidiasis, 1856
in Lyme arthritis, mouse model, 1512
in retinal necrosis pathogenesis, viral, 27
in *Schistosoma haematobium* infections, 512
Interleukin-5
in retinal necrosis pathogenesis, viral, 27
in *Schistosoma haematobium* infections, 512
Interleukin-6
in gram-negative bacteremia, 270
inhibition, lipopolysaccharide-induced, in systemic inflammatory response syndrome, 883
in Lyme arthritis, mouse model, 1512
in *Plasmodium falciparum* malaria, 520
Interleukin-8
in gram-negative bacteremia, 270
in *Haemophilus ducreyi* infection, 1688
from neutrophils
in *Escherichia coli* lipopolysaccharide response, 127
in *Mycobacterium tuberculosis* response, 127
in staphylococcal exotoxin induction, 573
Interleukin-10
in cytokine production inhibition, 1830
granulocyte colony-stimulating factor effects on, 891
in hepatosplenic candidiasis, 589
in interleukin-12 regulation, in *Mycobacterium tuberculosis* monocyte infections, 1105
measurement, in tetanus vaccination in onchocerciasis, 1133
in phagocytosis suppression, 1734
in *Plasmodium falciparum* malaria, 520
in varicella-zoster virus immune response, 940
Interleukin-11, in *Pseudomonas aeruginosa* sepsis, rat model, 1205
Interleukin-12
in aspergillosis immune response, mouse model, 1750
clarithromycin effects on, for *Mycobacterium avium* complex infections, mouse model, 896
*Cryptococcus neoformans* induction, 803
in hepatitis C, vs. hepatocellular damage, 247
in *Mycobacterium avium* complex infections, in HIV infection, 1209
regulation
in interferon-$\gamma$ receptor deficiency, in mycobacterial infections, 1095
in *Mycobacterium tuberculosis* monocyte infections, 1105
in varicella-zoster virus immune response, 940
Interleukin-15, *Cryptococcus neoformans* induction, 803
Interleukin-18, in interferon-$\gamma$ production, lipopolysaccharide-induced, 1830
Isoniazid, resistance to, *Mycobacterium tuberculosis*, mechanisms, 769

JC virus, in cerebrospinal fluid, in progressive multifocal leukoencephalopathy prognosis, 1816
Joint(s), inflammation, in Lyme disease, 1512

Kaposi's sarcoma (*See also* Human herpesvirus 8)
in HIV infection, 114
Ki-67 antigen, HIV load and, 1279
Kidney
transplantation
cytomegalovirus infections in
human herpesvirus 6 reactivation in, 1783
monitoring, polymerase chain reaction in, 1544
prediction, 626
human herpesvirus 8 reactivation in, 1791
tubular epithelial cells, apoptosis, *Escherichia coli* Shiga toxin in, 178
*Kingella kingae*, transmission, in day care center, 1848
*Klebsiella pneumoniae*, bacteremia, treatment, endo
KNI-272 protease inhibitor, for HIV infection, potency in monocytes/macrophages, 413

$\beta$-Lactams, resistance to, *Enterococcus faecium*, 159
Lactobacilli, vaginal
hydrogen peroxide-producing, vs. *Escherichia coli* colonization, urinary tract infection and, 446
nonoxynol-9 effects on, 441
Lamina propria, macrophages activation in, *Helicobacter pylori* urease in, 1516
Lamivudine, for HIV infection

in combination therapy, immunologic response to, 70
indinavir resistance and, 360
in pregnancy, 1327
response to, 662
Lectin, mannose-binding, *Plasmodium falciparum*, malaria severity and, 1221
*Legionella pneumophila*, bacteremia, treatment, endotoxemia in, 270
*Leishmania braziliensis*, detection, in scars, 911
*Leishmania chagasi*, infections, mouse model, 1847
Leishmaniasis, visceral, mouse model, 908
Lentiviruses (*See* Feline immunodeficiency virus; Human immunodeficiency virus)
Leptin
in antiinflammatory therapy, 887
in endotoxemia, 887
Leptospirosis, epidemiology, with pulmonary hemorrhage, Nicaragua, 1457
Leukocyte(s), transendothelial migration, *Cryptococcus neoformans* glucuronoxylomannan effects on, 1231
Leukocyte count, in HIV infection, highly active retroviral therapy effects on, 1299
Leukocyte protease inhibitor, degradation, *Trichomonas vaginalis* cysteine proteases in, 815
Leukoencephalopathy, progressive multifocal, prognosis, cerebrospinal fluid JC virus levels in, 1816
Lewis antigens, *Helicobacter pylori* cell binding independent, 1379
Ligase chain reaction
for *Chlamydia trachomatis*, 1707
for sexually transmitted diseases, in military population, 1202
Linear mapping assays, for human immunodeficiency virus, 1306
Lipoarabinomannan, *Mycobacterium tuberculosis*, in inflammation, 1839
Lipopolysaccharide (endotoxin) (*See also* Endotoxemia)
*Campylobacter jejuni*, molecular mimicry, in Guillain-Barré syndrome, 1549
in cytokine inhibition, in systemic inflammatory response syndrome, 883
cytokine response to, in HIV infection, granulocyte colony-stimulating factor effects on, 686
*Escherichia coli*
neutrophil response to, 127
O157 vs. O55, 920, 1551
in interferon-$\gamma$ induction, interleukin-18 enhancement, 1830
modulating proteins, in tuberculosis, 1839
tumor necrosis factor-$\alpha$ production by, surfactant effects on, 1122
Lipopolysaccharide-binding protein, in tuberculosis, 1839
*Listeria monocytogenes*, infections, brain microvascular endothelial cell activation in, 1658
Liver
candidiasis, interleukin-10 in, 589
damage, in hepatitis C, interleukin-12 in, 247
necrosis, in yellow fever, 1270
Lung
aspergillosis, mucosal immune response in, mouse model, 1750
*Aspergillus fumigatus* infections, mouse model, 1472
epithelial cells, *Haemophilus influenzae* adherence to, defensins in, 1067
Lyme disease
antibody response in
mouse model, 733
to outer surface proteins, 1676
arthritis in, mouse model, 1512
*Borrelia burgdorferi* gene expression during, erythema migrans vs. arthritis, 1198
neurologic, pathogenesis, rhesus monkey model, 722
vaccination, mouse model, 733
Lymph, lipopolysaccharide-induced cytokine production inhibition in, in systemic inflammatory response syndrome, 883
Lymphocyte(s) (*See* B cells; T cells)
Lymphocyte-reactive autoantibodies, in HIV infection, in T cell depletion, 404
Lymphoid tissue, hepatitis C virus replication in, in HIV infection, 1189

Macrophage(s)
activation, *Helicobacter pylori* urease in, 1516
alveolar, response to *Mycobacterium tuberculosis* antigens, in active tuberculosis, 1434
*Aspergillus fumigatus* infections, mouse model, 1472
*Candida albicans* interactions with, 792
HIV replication in, 388
indoleamine 2,3-dioxygenase in, in neonatal sepsis inhibition, 875
interleukin-12 secretion from, in *Mycobacterium avium* complex infections, in HIV infection, 1209
in nitric oxide synthase and nitric oxide production, pneumococci stimulation, mouse model, 1649
in peripheral nerves, in Lyme disease, rhesus monkey model, 722
in T cell destruction, in HIV infection, 404
tumor necrosis factor-$\alpha$ production in, suppression by bovine surfactant, genital mycoplasmas and, 1122
Macrophage inflammatory protein-1$\alpha$
in cervical secretions, in HIV infection, 1334
in *Escherichia coli* lipopolysaccharide response, 127
in *Mycobacterium tuberculosis* response, 127
in tuberculous pleurisy, 1450
Macrophage inflammatory protein-1$\beta$, in cervical secretions, in HIV infection, 1334
Major histocompatibility complex
genotypes, in HIV infection progression, 1799
hepatitis C virus clearance and, 39
Major outer membrane protein, *Chlamydia trachomatis*, T cell response to, serovar-specific, 1713
Major regulatory protein (IE62), varicella-zoster virus, nuclear localization, S16
Malaria
cerebral, convulsions in, mouse model, 1225
cysteine protease-related antigens in, humoral immune response to, 285
inflammation in, interleukin-10 in, 520
mannose-binding lectin levels in, protective effects, 1221
severe, susceptibility to, age-dependent, 592
testing for, viral hemorrhagic fever virus inactivation methods in, 1852
vaccination, efficacy, 1139
Mannose-binding lectin, *Plasmodium falciparum*, malaria severity and, 1221
Mannose-binding protein, in tumor necrosis factor-$\alpha$ production, in *Candida albicans* stimulation, 1734
Matrix metalloproteinase-9, in cerebrospinal fluid, in HIV infection, 854
Measles-like illnesses, after measles-mumps-rubella vaccination, 1567
Measles-mumps-rubella vaccination, measles-like and rubella-like illnesses after, 1567
Mechanical ventilation, in respiratory syncytial virus infections, monoclonal antibody treatment in, 1555
MEDI-493 monoclonal antibody, in respiratory syncytial virus infections, 1555
Medroxyprogesterone acetate, HIV infection transmission risk and, 1053
Meningitis
*Cryptococcus neoformans*, leukocyte transendothelial migration in, glucuronoxylomannan effects on, 1231

*Listeria monocytogenes*, brain microvascular endothelial cell activation in, 1658
*Neisseria meningitidis*, in Argentina, 266
Meningococci (*See also Neisseria meningitidis*)
infections, in Argentina, 266
vaccination, immunologic refractoriness in, 870
Meningoencephalitis, coccidioidal, rabbit model, 1217
Menstrual cycle, HIV shedding in, 983
Metalloproteinases, in cerebrospinal fluid, in HIV infection, 854
Methicillin, resistance to, *Staphylococcus aureus*, 164
in child care centers, 577
$\beta_2$-Microglobulin, in HIV infection, before CD4 T cell inflection point, 423
Microsporidiosis, in HIV infection, risk factors for, 904
Military recruits, *Neisseria meningitidis* colonization in, 451
Molecular mimicry, *Campylobacter jejuni* lipopolysaccharides, in Guillain-Barré syndrome, 1549
Molluscum contagiosum virus, immunoreactive proteins, 1230
Monoclonal antibodies
in convulsion prevention, in *Plasmodium berghei* cerebral malaria, mouse model, 1225
in cryptococcosis, mouse model, 1213
Monocyte(s)
CD4 expression on, organisms regulating, 1464
*Chlamydia pneumoniae* DNA in, in cardiovascular disease, 274
Fas and Fas ligand in, in HIV infection, 1030
granulocyte-macrophage colony-stimulating factor effects on, in sepsis, 1421
interleukin-8 release from, staphylococcal exotoxin induction, 573
interleukin-15 release from, *Cryptococcus neoformans* induction, 803
ytosis, suppression by interleukin-10, 1734
in T cell destruction, in HIV infection, 404
in tumor necrosis factor-$\alpha$ production, *Candida albicans* effects on, 1734
Monocyte chemoattractant protein-1, in tuberculous pleurisy, 1450
*Moraxella catarrhalis*, vaccination, mouse model, 1667
*Morganella morganii*, bacteremia, treatment, endotoxemia in, 270
Mortality
attributable, in antibiotic therapy, 917
in HIV infection, in pediatric patients
prediction, 680
in Zimbabwe, 109
in influenza, pandemics vs. epidemics, 53
Mucin, salivary, in HIV inhibition, 1635
Mucosal immune response
in aspergillosis, mouse model, 1750
to influenza vaccination, 933
Mucosal vaccines
HIV
mouse model, 1359
rabbit model, 850
*Moraxella catarrhalis*, mouse model, 1667
Multiple myeloma, human herpesvirus 8 antibodies in, 846
Mutations
CCR2, HIV syncytium-inducing variant and, 1806
CCR5, HIV infection progression and, 1019, 1163
*CD40L* gene, in X-linked hyper-IgM syndrome, 318
*Cryptococcus neoformans*, mouse model, 1761
cytochrome b gene, *Pneumocystis carinii*, prophylaxis failure and, 1767
dihydrofolate reductase, *Streptococcus pneumoniae* resistance in, 700
DNA polymerase, in cytomegalovirus foscarnet resistance, 526
enoyl reductase, *Mycobacterium tuberculosis*, 769
mannose-binding lectin gene, *Plasmodium falciparum*, malaria severity and, 1221
protease, HIV, 1497
thymidine kinase gene, in acyclovir-resistant herpes simplex virus type 1, 618
varicella-zoster virus
foscarnet resistance in, S55
glycoproteins, S22
*Mycobacterium avium* complex
genetic diversity, in pediatric patients, 776
infections
in HIV infection, 114
interleukin-12 production in, 1209
treatment, 1446
in interferon-$\gamma$ receptor deficiency, 1095
mouse model, 896
treatment, 121
tree kangaroo model, 1719
inhibition, granulocyte colony-stimulating factor in, in HIV infection, 1530
*Mycobacterium tuberculosis* (*See also* Tuberculosis)
antibodies to, investigation for serologic diagnosis, 1534
antigen 85 complex, in sputum, prognosis and, 1115
antigens, alveolar lymphocyte response to, in active tuberculosis, 1434
lipoarabinomannan, in inflammation, 1839
monocyte infections, cytokine regulation in, 1105
neutrophil response to, 127
resistance in, isoniazid, mechanisms, 769
T cell response to, factors affecting, 760
vaccination (*See* Bacille Calmette-Guérin)
*Mycoplasma hominis*, tumor necrosis factor-$\alpha$ production by, surfactant effects on, 1122
*Mycoplasma pneumoniae*, pneumonia, pathogenesis, mouse model, 1526
Myeloma, human herpesvirus 8 antibodies in, 846

Nasal vaccines, HIV, mouse model, 1359
National Congenital Rubella Syndrome Registry, data analysis, 636
Necrosis, retinal, viral, pathogenesis, T cells in, 27
*Neisseria gonorrhoeae*
infections
asymptomatic, epidemiology, in military population, 1202
HIV, infection transmission risk in, 1174
immune responses in, in concomitant infections, 742
transmission, 1707
salpingitis, in HIV infection, 1352
*Neisseria meningitidis*
colonization, in military recruits, 451
infections, in Argentina, 266
vaccination, immunologic refractoriness in, 870
Neonatal infections (*See also* Congenital infections)
chronic lung disease in, surfactant in, genital mycoplasmas and, 1122
hepatitis C, with HIV infection, 1047
HIV infection
prevention, 1327
treatment, 368
sepsis, streptococci group B, immune response in, 875
Neopterin, in HIV infection, before CD4 T cell inflection point, 423
Neuralgia, postherpetic, S76
prevention, S91
risk factors for, S71
treatment, cost effectiveness, S85
Neuroborreliosis, pathogenesis, rhesus monkey model, 722
Neuropathy, peripheral, in Lyme disease, rhesus monkey model, 722
Neurosyphilis, epidemiology, in HIV infection, New Orleans (1990–1997), 1229

Neutralization assays, for HIV, 1306
Neutrophils
apoptosis, inhibition, granulocyte colony-stimulating factor in, 891
*Aspergillus fumigatus* infections, mouse model, 1472
defensins, in *Haemophilus influenzae* adherence, to lung epithelial cells, 1067
response
to *Escherichia coli* lipopolysaccharide, 127
to granulocyte colony-stimulating factor, in HIV infection, *Mycobacterium avium* complex inhibition in, 1530
to *Mycobacterium tuberculosis*, 127
stimulation, with granulocyte colony-stimulating factor, for pneumonia, 1075
Nevirapine, for HIV infection, pharmacokinetics, 368
Nitric oxide synthase and nitric oxide production, pneumococci in, mouse model, 1649
*Nocardia farcinica*, sternotomy infections, 1539
Nonoxynol-9, vaginal lactobacilli effects, 441
Norwalk-like viruses, gastroenteritis, epidemiology, United States, 1571
Nosocomial infections
*Nocardia farcinica*, in sternotomy, 1539
torovirus gastroenteritis, 1263
Nuclear factor kappaB, in HIV transmission enhancement, 1343
Nuclear localization, major regulatory protein (IE62), varicella-zoster virus, S16
Nucleic acid sequence-based amplification technique, for cytomegalovirus, in bone marrow transplantation, 1244

Oka strain, varicella-zoster virus, molecular epidemiologic analysis, 35
$\beta$-1,2-Oligomannosides, *Candida albicans*, in macrophage interactions, 792
*Onchocerca volvulus*, detection, polymerase chain reaction in, 282
Onchocerciasis, tetanus vaccination in, impaired response, 1133
Open-reading frame 4, varicella-zoster virus, anatomy, S27
Open-reading frame 29, varicella-zoster virus, in gene modulation, S34
Opioids, in herpes zoster, S91
Opportunistic infections, in HIV infection
in drug abuse, 114
in homosexual population, 114
T cell antigens and, 1279
Opsonization, *Helicobacter pylori* urease effects on, 1521
Oropharyngeal colonization, pneumococci, anticapsular polysaccharide antibodies and, rat model, 878
Otitis media, treatment, 1547
Outbreaks
bloodstream infections, in hemodialysis, 783
botulism, Texas, 172
Norwalk-like virus gastroenteritis, United States, 1571
Outer membrane/surface proteins
*Borrelia burgdorferi*, antibodies to, 1676
mouse model, 733
*Chlamydia trachomatis*, T cell response to, serovar-specific, 1713
*Moraxella catarrhalis*, in vaccination, mouse model, 1667
Oysters, harvesting seasons, vs. *Vibrio vulnificus* infection epidemiology, 752

Pain, in herpes zoster (*See under* Herpes zoster)
Palivizumab (MEDI-493 monoclonal antibody), in respiratory syncytial virus infections, 1555
Pandemics, influenza, mortality in, vs. epidemics, 53
Paromomycin, for cryptosporidiosis, in HIV infection, 900, 915
Parvovirus B19
anemia from, in X-linked hyper-IgM syndrome, 318
infections, IgG response in, 1826
Parvoviruses, infections, after measles-mumps-rubella vaccination, simulating vaccine failure, 1567
Passive immunization, with anticapsular polysaccharide antibodies, pneumococcal colonization and, rat model, 878
Pediatric patients (*See also* Neonatal infections)
astroviruses infection epidemiology, Mayan Mexicans, 334
congenital infections in (*See* Congenital infections)
cytomegalovirus infections in
ganciclovir resistance in, 535
monitoring, in bone marrow transplantation, 1244
diarrhea in, etiology, Israeli Bedouins, 1081
*pylori* serologic testing in, 460
*Helicobacter pylori* serologic testing in, 460
HIV infection in
human herpesvirus 8 antibodies in, epidemiology, Zambia, 1787
human herpesvirus 6 infections in, diagnosis, 1250
cytotoxic T cell responses and, 1317
diagnosis, serology in, 560
hepatitis G with, 862
mortality in
predictors, 680
in Zimbabwe, 109
prevention, 1327
prognosis, 375
progression, CCR5 mutations in, 1019
treatment, 368
immune globulin in, 597
viral load vs. progression, 101
influenza vaccination, immune response in, 933
malaria in, mannose-binding lectin levels in, 1221
*Mycobacterium avium* complex in, genetic diversity, 776
respiratory syncytial virus infections in
attachment protein diversity in, 925
treatment, monoclonal antibodies, 1555
rotavirus infections in, natural protection after, 1562
torovirus gastroenteritis in, 1263
Pelvic inflammatory disease
HIV infection transmission risk in, 1174
in HIV infection, 1352
Penicillin-binding protein 5, alterations, *Enterococcus faecium*, 159
Pentoxifylline, in tuberculosis, in HIV infection, 1861
Peptic ulcer disease, *Helicobacter pylori* in (*See Helicobacter pylori*)
Peptides
HIV, CD8 T cells responsive to, quantification, 260
*Mycobacterium tuberculosis*, T cell response to, factors affecting, 760
Peripheral blood mononuclear cells, human herpesvirus 8 DNA in, 1610
Peripheral neuropathy, in Lyme disease, rhesus monkey model, 722
Peritonitis
*Enterococcus faecalis*, mutants, mouse model, 1416
polymicrobial, granulocyte colony-stimulating factor in, mouse model, 471
Pertactin, cellular immune response to, 466
Pertussis, vaccination, cellular immune response in, 466
Pesticides, *Bacillus popilliae*, vancomycin resistance in, 584
Peyer's patches, HIV vaccination in, rabbit model, 850
Phagocytosis, interleukin-10 effects on, 1734
Phospholipomannan, *Candida albicans*, in macrophage interactions, 792
Placenta, scrapie prions in, 949
Plague, transmission, by blocked fleas, *Yersinia pestis* plasminogen activator and, 1406
Plasmid vaccines, herpes simplex virus type 1, mouse model, 611
Plasminogen activator, *Yersinia pestis*, flea blocking and, 1406

*Plasmodium berghei*, cerebral malaria, convulsions in, mouse model, 1225
*Plasmodium falciparum*
cysteine protease-related antigens, humoral immune response to, 285
malaria
interleukin-10 in, 520
mannose-binding lectin levels in, 1221
susceptibility to, age-dependent, 592
testing for, viral hemorrhagic fever virus inactivation methods in, 1852
vaccination, efficacy, 1139
Pleurisy, tuberculous, chemokines in, 1450
Pneumococci (*Streptococcus pneumoniae*)
colonization, oropharyngeal, anticapsular polysaccharide antibodies and, rat model, 878
in nitric oxide synthase and nitric oxide production, mouse model, 1649
resistance in, trimethoprim, 700
vaccination
antibody response in, molecular structure, 707
in elderly persons, 431
*Pneumocystis carinii*, pneumonia
antigens in, mouse model, 235
cytochrome b gene sequence polymorphisms, 1767
in human immunodeficiency virus infection, 114
risk factors for, 1126
viral load in, 1642
prophylaxis, failure, 1767
Pneumonia
in HIV infection, 114
viral load in, 1642
*Mycoplasma pneumoniae*, pathogenesis, mouse model, 1526
*Pneumocystis carinii*
antigens in, mouse model, 235
in HIV infection, 114
risk factors for, 1126
viral load in, 1642
prophylaxis, failure, 1767
respiratory syncytial virus, treatment, monoclonal antibodies, 1555
treatment, granulocyte colony-stimulating factor, 1075
Polyethylene glycol formulation, interleukin-2, in HIV infection, 992
Poly-(1-6)-$\beta$-glucotriosyl-(1-3)-$\beta$-glucopyranose glucan, for abdominal sepsis, rat model, 200
Polymerase chain reaction
for *Bacillus popilliae*, 584
for *Borrelia burgdorferi*, 722, 1198
for chemokines, in tuberculous pleurisy, 1450
for *Chlamydia pneumoniae*, 274
for *Chlamydia trachomatis*, 1707
for cytomegalovirus, 1860
in bone marrow transplantation, 1233, 1244
glycoprotein B, 1149
in kidney transplantation, 626, 1544
statistics in, 921
for Ebola virus, 651
for *Encephalitozoon intestinalis*, 820
for enteroviruses, 256
for feline immunodeficiency virus, 960
for genital ulcer organisms, 243, 1795
for *Haemophilus ducreyi*, 1060
for hepatitis C virus, 1189
for hepatitis G virus, 1779
for hepatitis viruses, 325
for herpes simplex virus type 2 glycoprotein, 8
for human herpesvirus 6, 544, 1250
for human herpesvirus 8, 1610, 1791
for human papillomavirus, 45, 252, 1492, 1604
for *Leishmania braziliensis*, 911
for *Onchocerca volvulus*, 282
reverse transcriptase
for cytokines, 1516
for HIV, 1642
for *Treponema pallidum*, 1060
for varicella-zoster virus, S64
Oka strain, 35
rat model, S48
Polymicrobial infections, sepsis, granulocyte colony-stimulating factor in, mouse model, 471
Polysaccharides
antibodies to, pneumococcal colonization and, rat model, 878
immunomodulating, for abdominal sepsis, rat model, 200
Postherpetic neuralgia, S76
prevention, S91
risk factors for, S71
treatment, cost effectiveness, S85
Potatoes, botulism from, Texas, 172
pPla virulence plasmid, *Yersinia pestis*, in flea blockage, 1406
Praziquantel, for *Schistosoma haemobium* infections, immune response and, 289
Pregnancy
HIV infection in
cat model, 960
cytotoxic T cell responses in, transmission and, 1317
with hepatitis C, 1047
treatment, 368, 1327
immune globulin in, 597
varicella-zoster virus infection in, congenital defects from, 539
Primary combined immunodeficiency, cytomegalovirus infections in, ganciclovir resistance in, 535
Prion proteins
pathologic, in scrapie and bovine spongiform encephalopathy, 693
tissue distribution, in scrapie, 949
Progenitor cells, function, in HIV infection, highly active retroviral therapy effects on, 1299
Progesterone levels, vs. HIV shedding, 983
Progressive multifocal leukoencephalopathy, prognosis, cerebrospinal fluid JC virus levels in, 1816
Prophylaxis, Ebola hemorrhagic fever, mouse model, 651
Prostaglandin A, in rotavirus replication inhibition, 564
Protease, HIV, mutations, drug resistance in, 1497
Protease inhibitors, for HIV infection, potency in monocytes/macrophages, 413
Protein F1, streptococci group A (*Streptococcus pyogenes*), in epithelial cell entry, 147
Proteinase K–resistant protein, in scrapie, 949
*Proteus mirabilis*, bacteremia, treatment, endotoxemia in, 270
*Pseudomonas aeruginosa*
bacteremia, treatment, endotoxemia in, 270
sepsis, rat model, 1205
Psychosocial factors, in herpes zoster, in elderly persons, S67
Publications, Infectious Diseases Society of America, August 1998, page E1
Pulmonary hemorrhage, in leptospirosis, epidemiology, Nicaragua, 1457
Purified protein derivative
alveolar lymphocyte response to, in tuberculosis, 1434
*Mycobacterium tuberculosis*, neutrophil response to, 127
Q fever, endocarditis, guinea pig model, 278

Racial factors, in herpes zoster, in elderly persons, S67

RANTES, in cervical secretions, in HIV infection, 1334
Resistance, drug (*See* Drug resistance)
Respiratory infections (*See also* Pneumonia)
  aspergillosis, mucosal immune response in, mouse model, 1750
  *Aspergillus fumigatus*, mouse model, 1472
  *Haemophilus influenzae*, adherence factors in, 1067
  *Mycobacterium avium* complex, treatment, 121
Respiratory syncytial virus
  infections
    attachment protein diversity in, rat model, 925
    treatment, monoclonal antibodies, in pediatric patients, 1555
  vaccination, rat model, 925
Responder cell frequency, varicella-zoster virus, S95
Restriction fragment length polymorphisms, for varicella-zoster virus, S64
Retina, necrosis, pathogenesis, virus-specific T cells in, 27
Retinitis, cytomegalovirus
  antiviral susceptibilities, 1821
  in HIV infection, 114
    glycoprotein B subtyping in, 1149
Retinoic acid, in T cell apoptosis inhibition, in HIV infection, 1288
*rev* gene, human immunodeficiency virus, in DNA-based vaccines, 92
Reverse transcriptase, HIV, mutations, drug resistance in, 1497
*rfaJ* gene, *Helicobacter pylori* vacuolating cytotoxin, 1391
Ribotyping, *Kingella kingae*, 1848
Rifabutin, for *Mycobacterium avium* complex infections, 121
  with HIV infection, 1446
Ritonavir, for HIV infection
  in combination therapy, immunologic response to, 70
  potency in monocytes/macrophages, 413
  resistance to, 1497
River blindness (onchocerciasis)
  diagnosis, polymerase chain reaction in, 282
  tetanus vaccination in, impaired response, 1133
Rotavirus
  infections, natural protection after, 1562
  replication, prostaglandin inhibition, 564
Rubella
  epidemiology
    congenital, United States, 636
    molecular analysis, North America, Europe, Asia, 642
  vaccination, maternal missed opportunities, 636
Rubella-like illnesses, after measles-mumps-rubella vaccination, 1567
Rubeola virus, antibodies to, in HIV infection, 1177

S gene mutant, hepatitis B, in thymosin $\alpha_1$ therapy, 866
*Saccharomyces*, fibronectin binding to, hemoglobin effects on, 497
Saliva
  human herpesvirus 8 DNA in, 1610
  in HIV inhibition, 1635
Salpingitis, in HIV infection, 1352
Saquinavir, for HIV infection
  in combination therapy, 340
  potency in monocytes/macrophages, 413
  resistance to, 1497
Sarcoma, Kaposi's (*See* Human herpesvirus 8; Kaposi's sarcoma)
Scars, *Leishmania braziliensis* detection in, 911
*Schistosoma haematobium*
  antigens, in interleukin production, 512
  immune response to, chemotherapy effects on, 289
Scientific inference, statistics and, 921
Scrapie prions
  strain variation, molecular analysis, 693
  tissue distribution, 949
Secretory leukocyte protease inhibitor, degradation, *Trichomonas vaginalis* cysteine proteases in, 815
Seizures, in *Plasmodium berghei* cerebral malaria, treatment, mouse model, 1225
Selectins, in *Listeria monocytogenes* infections, 1658
Semen, human herpesvirus 8 DNA in, 1610
Sepsis
  abdominal, rat model, 200
  gram-negative, treatment, endotoxemia in, 270
  monocyte anergy in, granulocyte-macrophage colony-stimulating factor effects on, 1421
  neonatal, streptococci group B, immune response in, 875
  nitric oxide synthase and nitric oxide production in, mouse model, 1649
  polymicrobial, granulocyte colony-stimulating factor in, mouse model, 471
  *Pseudomonas aeruginosa*, rat model, 1205
Serine-repeat antigens, *Plasmodium falciparum*, humoral immune response to, 285
Sexually transmitted diseases (*See also specific diseases*)
  asymptomatic, epidemiology, military populations, 1202
  HIV, transmission risk in, 1053, 1174
  polymerase chain reaction investigation, Mississippi, 1060
  human herpesvirus 8, 1488
    in Honduras, 547
Sheep, scrapie prion tissue distribution in, 949
Shellfish harvesting seasons, vs. *Vibrio vulnificus* infection epidemiology, 752
Shiga toxins, *Escherichia coli*, in renal tubular epithelial cell apoptosis, 178
Shingles (*See* Herpes zoster)
Shock, septic (*See* Sepsis)
Sialidase, vaginal, in bacterial vaginosis, 1698
Signal transduction, *Candida albicans*, glycolipid shedding in, 792
Single-strand conformational polymorphism, for varicella-zoster virus Oka strain, 35
Sinusitis, in HIV infection, viral load in, 1642
Skin
  human herpesvirus 8 DNA in, 1610
  *Leishmania braziliensis* detection in, 911
  scratches, *Onchocerca volvulus* detection in, 282
Skin tests, for anergy, in HIV infection, vs. CD4 T cell function, 1024
Spanish influenza (1918-1919), epidemiology, mortality in, 53
Spermicides, nonoxynol-9, vaginal lactobacilli effects, 441
Spleen, candidiasis, interleukin-10 in, 589
Splenectomy, in convulsion prevention, in *Plasmodium berghei* cerebral malaria, mouse model, 1225
Spongiform encephalopathy, transmission, 949
Sputum, *Mycobacterium tuberculosis* antigens in, prognosis and, 1115
Squamous intraepithelial lesions
  anorectal, in HIV infection, in homosexual men, 45
  cervical, in human papillomavirus infections, 252, 1604
Staphylococci, exotoxins, in interleukin-8 production, 573
*Staphylococcus aureus*
  phagocytosis, interleukin-10 effects on, 1734
  resistance in, methicillin, 164
    in child care centers, 577
Statistics, scientific inference and, 921
Stavudine, for HIV infection, response to, 662
Stem cells, HIV infection, chemokine receptors in, 1623
*Stenotrophomonas maltophilia*, bacteremia, in hemodialysis, 783
Sternotomy, *Nocardia farcinica* infections, 1539
Stomach, gastric cells in, *Helicobacter pylori* binding to, Lewis antigen–independent, 1379

Streptococci
group A (*Streptococcus pyogenes*), protein F1, in epithelial cell entry, 147
group B
invasive infections, antibody responses in, 569
neonatal sepsis, immune response in, 875
*Streptococcus pneumoniae* (*See* Pneumococci)
*Streptococcus pyogenes* (*See* Streptococci, group A)
Streptomycin, for *Mycobacterium avium* complex infections, 121
Stress, herpes zoster in, S67
Strongyloidiasis, human T lymphotropic virus type I infection with, cytokine response in, 1856
Surface plasmon resonance studies, for HIV, 1306
Surfactant, bovine, in tumor necrosis factor-$\alpha$ suppression, genital mycoplasmas and, 1122
Surgical infections
*Nocardia farcinica*, 1539
polymicrobial, granulocyte colony-stimulating factor in, mouse model, 471
Susceptibility testing
cytomegalovirus, 1821
ganciclovir, 531
Syncytium-inducing variant, HIV infection progression and
conversion from non–syncytium-inducing variant, 1806
in drug users, 388
in homosexual population, 397
Syphilis (*See also Treponema pallidum*)
diagnosis, molecular methods for, 243
epidemiology, in HIV infection, New Orleans (1990–1997), 1229
false-negative test for, 294
HIV infection transmission risk in, 1174
Systemic inflammatory response syndrome, lipopolysaccharide-induced cytokine production inhibition in, 883

T cells
antigens, for proliferation, HIV viral load and, 1279
apoptosis, in HIV infection
Fas and Fas ligand in, 1030
in nonprogressors, 669
retinoic acid inhibition, 1288
in *Candida albicans* antigen recognition, in HIV infection, 488
CD4
antigens, for proliferation, HIV viral load and, 1279
apoptosis
in HIV infection, retinoic acid inhibition, 1288
in HIV infection nonprogressors, 669
in HIV infection
vs. CCR5 mutations, 1019
*Pneumocystis carinii* pneumonia risk in, 1126
vs. time, 1166
vs. hypersensitivity skin test anergy, in HIV infection, 1024
inflection point, in HIV infection, vs. viral load, 423
in *Leishmania chagasi* infections, mouse model, 1847
response
to HIV, in antiretroviral triple therapy, 70
to varicella-zoster virus peptides, S39
in zidovudine therapy, for primary HIV infection, 80
CD4CD8 double-positive, cytotoxic function, in HIV infection, 1158
CD8
antigens, for proliferation, HIV viral load and, 1279
characteristics, in feline immunodeficiency virus infection, 968
depletion, in HIV infection, lymphocyte-reactive autoantibodies in, 404
in HIV infection
measurement, 260
response to antiretroviral triple therapy, 70
vs. time, 1166
CD34, in HIV infection
chemokine receptors in, 1623
highly active retroviral therapy effects on, 1299
CD95, apoptosis, in HIV infection, retinoic acid effects on, 1288
cytotoxic (*See also* T cells, CD8)
in HIV infection
in antiretroviral triple therapy, 61, 70
CD4CD8 double-positive, 1158
cross-clade response, 1040
gag-specific response in, 1008
in pediatric patients, 1317
depletion, in HIV infection
in *Candida albicans* infections, 488
with dual-tropic variants, in drug users, 388
lymphocyte-reactive autoantibodies in, 404
with syncytium-inducing variant, 1806
in homosexual population, 397
Fas and Fas ligand in, in HIV infection, 1030
functional assays for, in HIV infection, 1024
granulocyte colony-stimulating factor effects on, in HIV infection, 686
helper
in aspergillosis, 1750
in Lyme arthritis, mouse model, 1512
herpes simplex virus-specific, in retinal necrosis pathogenesis, 27
in *Mycobacterium tuberculosis* infections, factors affecting, 760
response
to *Chlamydia trachomatis*, serovar-specific, 1713
to *Haemophilus ducreyi*, 1688
to herpes simplex virus type 1, granulocyte-macrophage colony-stimulating factor production in, rat model, 16
to varicella-zoster virus, S95, 940
varicella-zoster virus-specific, in retinal necrosis pathogenesis, 27
Tetanus, vaccination, impaired response in onchocerciasis, 1133
Thymidine kinase gene, mutation, in acyclovir-resistant herpes simplex virus type 1, 618
Thymosin $\alpha_1$, for hepatitis B, S gene mutant emergence in, 866
Thymus
dysfunction, in HIV infection mortality prediction, 680
feline immunodeficiency virus in, 960
Tiny Tim character, diagnosis, 596
Torovirus, gastroenteritis, in pediatric patients, 1263
Toxic shock syndrome, staphylococcal, interleukin-8 in, 573
Toxoplasmosis
in feline immunodeficiency virus infection, interleukin ratios in, 503
in HIV infection, 114
interleukin ratios in, cat model, 503
viral load in, 1642
Transforming growth factor-$\beta$
in interleukin-12 regulation, in *Mycobacterium tuberculosis* monocyte infections, 1105
in *Neisseria gonorrhoeae* infections, in concomitant infections, 742
Trans-Golgi network, varicella-zoster virus in, S7
Transplantation
bone marrow
cytomegalovirus infections in
antibody kinetics, 1233
ganciclovir susceptibility, 531
monitoring in pediatric patients, 1244
prophylaxis, 1153

herpes simplex virus infections in, type 1, acyclovir-resistant, 618
cytomegalovirus infections in, antibody acquisition in, 1145
kidney
cytomegalovirus infections in
human herpesvirus 6 reactivation in, 1783
monitoring, polymerase chain reaction in, 1544
prediction, 626
human herpesvirus 8 reactivation in, 1791
*Treponema pallidum*
epidemiology, Mississippi, 1060
false-negative test for, 294
in genital ulcers, epidemiology, 1795
infections, diagnosis, molecular methods for, 243
*Trichomonas vaginalis*
cysteine proteases, in secretory leukocyte protease inhibitor degradation, 815
infections
HIV infection, transmission risk in, 1174
with *Neisseria gonorrhoeae* infections, immune response in, 742
*Trichosporon*, fibronectin binding to, hemoglobin effects on, 497
Trimethoprim, resistance to, *Streptococcus pneumoniae*, 700
Triton X-100, in viral hemorrhagic fever virus inactivation, in malaria testing, 1852
L-Tryptophan, depletion, in neonatal sepsis pathogenesis, 875
Tuberculosis (*See also Mycobacterium tuberculosis*)
active, alveolar lymphocyte response in, 1434
in HIV infection, 114
pentoxifylline safety in, 1861
lipopolysaccharide activity-modulating proteins in, 1839
pleurisy in, chemokines in, 1450
T cell response in, factors affecting, 760
treatment, deterioration after, 580
Tubo-ovarian abscess, in HIV infection, 1352
Tumor(s), cervical, human papillomavirus in, 252
Tumor necrosis factor-$\alpha$
in acute infections, in HIV infection, 1642
in aspergillosis immune response, mouse model, 1750
in *Aspergillus fumigatus* infections, mouse model, 1472
*Candida albicans* effects on, 1734
genes, amphotericin B activation of, 1726
in gram-negative bacteremia, 270
granulocyte colony-stimulating factor effects on, 891
in *Haemophilus ducreyi* infection, 1688
in *Helicobacter pylori* urease induction, 1516
in HIV infection, from CD4CD8 double-positive T cells, 1158
increased, after severe tuberculosis treatment initiation, 580
inhibition, lipopolysaccharide-induced, in systemic inflammatory response syndrome, 883
in interleukin-12 regulation, in *Mycobacterium tuberculosis* monocyte infections, 1105
in *Plasmodium falciparum* malaria, 520
regulation, in interferon-$\gamma$ receptor deficiency, in mycobacterial infections, 1095
in retinal necrosis pathogenesis, viral, 27
in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 1421
suppression by bovine surfactant, genital mycoplasmas and, 1122
Tumor necrosis factor receptor
granulocyte colony-stimulating factor effects on, 891, 1421
in HIV infection
in acute infections, 1642
before CD4 T cell inflection point, 423
in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 1421

Ulcer(s)
genital (*See also* Chancroid)
etiology, 1795
herpes simplex virus, diagnosis, molecular methods for, 243
HIV infection transmission risk and, 1053
HIV infection with, 1795
peptic, *Helicobacter pylori* in (*See Helicobacter pylori*)
Umbilical cord, stem cells in, HIV infection, chemokine receptors in, 1623
*Ureaplasma urealyticum*, tumor necrosis factor-$\alpha$ production by, surfactant effects on, 1122
Urease, *Helicobacter pylori*
in mucosal macrophage activation, 1516
opsonization effects, 1521
Urethritis, sexually transmitted disease transmission in, 1707
Urinary tract infections, in vaginal *Escherichia coli* colonization, vs. hydrogen peroxide-producing lactobacilli, 446
Uveitis, varicella-zoster virus, guinea pig model, 310

*vacA* gene and product, *Helicobacter pylori*, 207, 220
sequence analysis, in cytotoxic and noncytotoxic strains, 1391
Vaccination
bacille Calmette-Guérin
percutaneous, cellular immune response, 138
T cell repertoire in, 760
*Bordetella pertussis*, cellular immune response in, 466
*Candida*, vaginal, mouse model, 227
Ebola virus, mouse model, 651
*Helicobacter pylori*, pig model, 1399
hepatitis A virus
dose response study, 1181
epidemiology patterns and, 1579
hepatitis B virus, 954
herpes simplex virus type 1, glycoprotein subunit, antibody response to, mouse model, 611
herpes simplex virus type 2, glycoprotein subunit, cervical antibody responses to, 1
HIV
clinical trials, 92
diverse clades and, 1040
mouse model, 1359
neutralizing activity in, 1502
rabbit model, 850
influenza virus, immune response in, 933
Lyme disease, mouse model, 733
malaria, efficacy, 1139
measles-mumps-rubella, measles-like and rubella-like illnesses after, 1567
meningococcal, immunologic refractoriness in, 870
*Moraxella catarrhalis*, mouse model, 1667
mucosal (*See* Mucosal vaccines)
*Mycobacterium tuberculosis* (*See* Bacille Calmette-Guérin)
*Neisseria meningitidis*, immunologic refractoriness in, 870
pertussis, cellular immune response in, 466
*Plasmodium falciparum*, efficacy, 1139
pneumococcal
antibody response in, molecular structure, 707
in elderly persons, 431
respiratory syncytial virus, rat model, 925
rubella, maternal missed opportunities, 636
tetanus, impaired response in onchocerciasis, 1133
varicella-zoster virus
booster doses, S109

vs. costs of chickenpox, S58
cytokine production in, 940
herpes zoster prevention, S91
in older adults, S99, S109
Vacuolating cytotoxins, *Helicobacter pylori*, 207, 220
enterotoxic effect, in vitro studies, 1373
*vacA* gene sequence analysis, 1391
Vagina
candidiasis, vaccination, mouse model, 227
*Escherichia coli* colonization, vs. hydrogen peroxide-producing lactobacilli, urinary tract infection and, 446
lactobacilli in, nonoxynol-9 effects on, 441
Vaginitis (*See also* Bacterial vaginosis)
HIV infection transmission risk and, 1053
Valaciclovir
for herpes simplex virus infections, recurrent, 603
for herpes zoster, S81
cost effectiveness, S85
*van* genes, *Bacillus popilliae* DNA sequence resembling, 584
Vancomycin, resistance to, *Bacillus popilliae*, 584
Varicella-zoster virus
cellular immune response, in depression, S104
in cytokine production, S95
endocytosis, S2
gene, expression, regulation, S27, S34
glycoproteins
analysis, S22
characteristics, S2, S13
immune response to, guinea pig model, 310
intracellular transport, S7
open-reading frame 29 binding to, S34
purification, S13
recombinant, in baculovirus system, S13
IE 63 protein, immune response to, S43
infections
adult susceptibility to, in tropics, S52
congenital, Barrett's esophagus in, 539
economic costs, France, S58
herpes zoster in (*See* Herpes zoster)
in HIV infection, S55
prevention with acyclovir, 349
immune response in, IE 63 protein in, S43
pathogenesis, glycoproteins in, S22
latency
IE 63 protein in, S43
open-reading frame 29 protein in, S34
rat model, S48
major regulatory protein (IE62), nuclear localization, S16
Oka strain, molecular epidemiologic analysis, 35
open-reading frame 4 promotor, anatomy, S27
open-reading frame 29, in gene modulation, S34
peptides, immune response to, dendritic cell assay for, S39
replication, glycoproteins in, S22
resistance in, foscarnet, S55
retinal necrosis, pathogenesis, T cells in, 27
strains, identification, S64
uveitis, guinea pig model, 310
vaccination
booster doses, S109
vs. costs of chickenpox, S58
cytokine production in, 940
herpes zoster prevention, S91
in older adults, S99, S109
Vascular cell adhesion molecules, in *Listeria monocytogenes* infections, 1658
Vasculitis, *Coccidioides immitis*, rabbit model, 1217
$V_H3$ gene, usage, in *Streptococcus pneumoniae* vaccination, 707
*Vibrio vulnificus*, epidemiology, vs. oyster harvesting season, 752
Viral hemorrhagic fever viruses, inactivation, in malaria testing, 1852
Viral infections, in HIV infection, viral load in, 1642
Virulence factors
*Cryptococcus neoformans*
in HIV infection, mouse model, 1761
monoclonal antibodies to, mouse model, 1213
*Enterococcus faecalis*, mouse model, 1416
*Haemophilus ducreyi*, 191
*Helicobacter pylori*, 207, 220, 1373
streptococci, group A (*Streptococcus pyogenes*), 147
Visceral leishmaniasis, mouse model, 908
Vitreous, cytomegalovirus in, glycoprotein B subtyping n, 1149
Vitronectin, in tumor necrosis factor-α production, in *Candida albicans* stimulation, 1734
Vulvitis, HIV infection, transmission risk and, 1053

Warts, genital (*See* Human papillomavirus)
Waterborne diseases
leptospirosis, with pulmonary hemorrhage, 1457
microsporidiosis, in HIV infection, 904
*Schistosoma haematobium* infections, interleukin production in, 512
*Vibrio vulnificus* infections, vs. oyster harvesting season, 752
Western blot test
for *Kingella kingae*, 1848
*Neisseria meningitidis*, 451
Wound infections, *Vibrio vulnificus* infections, vs. oyster harvesting season, 752

*Xenopsylla cheopis* (flea), in plague transmission, *Yersinia pestis* plasminogen activator and, 1406
X-linked hyper-IgM syndrome, parvovirus B19–induced anemia in, 318

Yellow fever, pathogenesis, vs. dengue fever, 1270
*Yersinia pestis*, plasminogen activator, flea blocking and, 1406

Zanamivir, for influenza
mouse model, 1592
resistance to, 1257
Zidovudine, for HIV infection
in combination therapy, 340
immunologic response to, 70
indinavir resistance and, 360
with interleukin-2, 1170
in pregnancy, 1327
primary, 80
response to, 662
Zoster (*See* Herpes zoster)
Zymography, in metalloproteinase detection, in cerebrospinal fluid, in HIV infection, 854